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Abstract

Current prognostic techniques for Cutaneous Malignant Melanoma (CMM), a
highly aggressive and drug resistant skin cancer, are inadequate at managing
the disease and identifying early stage patients requiring treatment. It is
thought that Circulating Tumour Cells (CTCs ), which circulate in patient blood
after being shed from solid tumours, may be useful in enhancing prognostic
techniques and it has previously been shown in other malignancies that the
presence of CTCs in patient blood is associated with poor prognosis. In CMM,
CTCs can be detected through RT-PCR for melanoma associated markers,
although this technique does not allow CTCs to be quantified.

In this study, melanoma CTCs were isolated from patient peripheral blood
samples with a combination of MCSP, MCAM and ABCB5 antibody coupled
immunomagnetic

beads

and

were

subsequently

quantified.

The

immunomagnetic bead capture protocol was performed for 21 control and 33
patient blood samples ranging from clinical stage 0 to IV. Results showed a
significant difference between the mean number of cells captured from control
(mean=3. 71) and patient (mean=24.45) blood samples (p=0.01 ). Furthermore,
there was a significant relationship between the number of MCAM positive
CTCs and disease stage (r=0.486, p=0.004 ), although there were ·no
significant relationships between the number of MCSP positive, ABCB5
positive or total CTCs and disease stage. Overall, this study has identified
MCAM positivity as a CTC marker associated with disease progression which
may be useful in improving prognostic testing and disease management in
melanoma patients.
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1. Introduction

Cutaneous Malignant Melanoma (CMM) is a highly aggressive skin cancer which is
notoriously resistant to currently available cancer therapies. Although CMM only
accounts for a small percentage of skin cancers, it is responsible for 80% of skin
cancer related deaths (Lewis et al., 2005). Australia, along with New Zealand, North
America and Northern Europe, has the highest incidence rate of melanoma
worldwide (Villanueva & Herlyn, 2009). Disease outcome is largely determined by
progression at the time of diagnosis. Patients with in-situ melanoma at time of
detection have a very high probability of relapse free survival following surgical
resection of the primary tumour, whereas those with metastatic disease at time of
detection have poor prognosis. Currently available prognostic techniques, including
primary tumour thickness and detection of metastasis in regional lymph nodes, have
proved to be inadequate as 30% of patients with in situ melanoma (Koyanagi et al.,
2005a) and 15% of patients with negative lymph nodes at the time of surgical
'intervention (Jack et al., 2006; Weight et al., 2006) go on to develop metastatic
disease.

It is thought that the number of melanoma cells circulating in patient peripheral blood
may be a useful prognostic measure although, at this time, circulating cells have not
been effectively quantified in patients across all stages of disease. The presence of
circulating melanoma cells can be detected by reverse-transcriptase polymerase
chain reaction (RT-PCR) of melanoma associated markers in patient blood and
results of previous studies have shown that detection of these markers correlates
with poor prognosis (Arenberger et al., 2008; Hoon et al., 1995; Hoon et al., 2000;
Koyanagi et al., 2005a; Lewis et al., 2005; Reynolds et al. 2003). This technique has
demonstrated that circulating cells are present in peripheral blood of patients across
clinical stages I to IV, even though there is no clinical evidence of metastasis in
stage I and II patients (Hoon et al., 1995; Hoon et al., 2000; Koyanagi et al., 2005a).
The fact that many stage 0, I and II patients later develop metastatic disease, even
years after surgical intervention, suggests circulating tumour cells are involved in the
formation of metastases and may therefore be useful in evaluating prognosis in early
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stage patients. The major limitation of RT-PCR detection of circulating cell markers is
that it does not allow circulating cells to be quantified.

In order to quantify circulating melanoma cells it is first necessary to isolate them
from patient blood samples. Currently, the most promising method of isolating
circulating melanoma cells is by immunomagnetic bead capture, where cells are
targeted specifically by magnetic beads bound to melanoma antigen specific
antibodies. This technique has been shown to be effective at isolating circulating
melanoma cells (Faye et al., 2004; Kitago et al. 2009; Ulmer et al., 2004), although
cells have not been able to be isolated in all tested patients. In this study, a
combination of Melanoma-Associated Chondroitin Sulphate Proteoglycan (MCSP),
Melanoma Cell Adhesion Molecule (MCAM) and ATP-Binding Cassette Subfamily 8
Member 5 (ABCBS) antibodies coupled to immunomagnetic beads were used for
optimal isolation and subsequent quantification of circulating melanoma cells from
patients of American Joint Committee on Cancer (AJCC) stages 0 to IV, in order to
'determine the relationship between the number of melanoma circulating cells and
disease stage.

2

2. Literature Review

2.1. Cutaneous Malignant Melanoma

Cutaneous Malignant Melanoma is a highly aggressive and drug resistant form of
skin cancer. Melanoma arises from melanocytes, the melanin pigment producing
cells of the skin, which are of neuroectodermal origin (Fiorenes et al., 1994). During
embryogenesis, pluripotent cells of the neural crest migrate to the skin, hair and eyes
where they differentiate into melanocytes capable of producing melanin (Goding,
2007). Melanoma only accounts for 4% of skin cancers although it is responsible for
80% of skin cancer related deaths (Lewis et al., 2005). Australia, New Zealand,
North America and Northern Europe have the highest incidence of melanoma
worldwide (Villanueva & Herlyn, 2009). In Western Australia, melanoma has the
highest incidence of any cancer in both males and females aged 15 to 39 {Threlfall &
Thompson, 2009). Survival of the disease is largely dependent on progression at
time of detection, particularly the extent of metastasis. Current prognostic techniques
and treatments are ineffective at managing the disease and unless diagnosis and
treatment occurs before the onset of metastasis, prognosis is extremely poor.

2.2. Melanoma Development

Melanomas can originate from existing naevi, circular areas of dark pigmentation on
the skin, or can arise spontaneously (Tan, 201 0). The most common cause of
melanoma is excessive exposure to ultraviolet (UV) radiation, with both UVA and
UVB wavelengths being implicated (Leiter & Garbe, 2008; Villanueva & Herlyn,
2009). Initially,

melanocyte~

undergo proliferation resulting in the formation of benign

naevi which may or may not progress to radial growth phase melanomas.
Melanomas undergo two growth phases, a radial growth phase (RGP) where growth
is superficial within the epidermis and a vertical growth phase (VGP) where the
tumour increases in thickness invading deeper tissue layers (Fig 2.1.). Once the
lesion has entered the vertical growth phase it becomes capable of metastasis as a
result of invasion of subcutaneous tissue and entry into lymphatic and circulatory
vessels (Fig 2.2.). Studies have shown that vertical growth phase cells are capable
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of tumour formation when injected into immunodeficient mice (Villanueva & Herlyn,
2009).

Melanocyte
precursor

Differentiated
melanocyte

Fibroblasts -Endothelial-Immune
cells
cell5
Tumour microenvi ron ment

Figure 2.1. Typical pathway of melanoma development (Villanueva & Herlyn, 2009)

Primary tumour thickness is used as a prognostic indicator as increased thickness is
associated with an increased number of metastases. Clinically, a tumour is regarded
as thin if it is less than one millimetre in thickness, moderate if between one and four
millimetres in thickness and thick if it is greater than four millimetres in thickness
(Tan, 201 0). Patients with a primary tumour thickness of less than 0.75mm have a
95% cure rate while patients with a primary tumour greater than 4mm in thickness
have a cure rate of 20-25% (Breslow, 1970; Kerbel, 1990).

Figure 2.2. Diagram illustrating the ability of tumours to metastasise via the circulatory system
(Pantel et al., 1999)
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2.3. Mutations

The development of melanoma is multifactorial although, as mentioned previously,
the major cause is excessive exposure to UV radiation. Melanocytes are normally
under the control of adjacent keratinocytes which release chemical signals regulating
proliferation and cell-cell adhesion, however, altered expression of regulating genes
can result in uncontrolled proliferation and detachment of melanocytes (Haas et al.,
2005). Approximately 10% of melanomas appear in genetically predisposed
individuals, that is individuals with fair skin, increased freckling and red hair and a
further 10% of cases are familial, appearing in individuals with a family history of the
disease (Villanueva & Herlyn, 2009). Individuals with a large number of atypical or
dysplastic nevi are also at greater risk of developing melanoma. There are a number
of pathways and mutations associated with melanoma development. Genetic
predisposition can be the result of polymorphisms in the Melanocortin-1 Receptor
(MC1 R) gene which are associated with red hair, fair skin and freckling (Villanueva &
Herlyn, 2009). Inherited mutations in the CDKN2A and CDK4 genes are associated
with familial melanoma, with CDKN2A mutations being the most frequent. CDK4
mutations are also regularly seen in sporadic melanomas where, like the majority of
melanoma associated mutations, they develop spontaneously (Villanueva & Herlyn,
2009).

Other sporadic mutations commonly found in melanomas occur in oncogenes.
Oncogenes, which in their normal form (proto-oncogenes) regulate cell proliferation,

I

promote uncontrolled cell division contributing to tumour formation. The most
common oncogene implicated in melanoma formation is BRAF, which is mutated in
approximately 60% of naevi and melanomas (Davies et al., 2002). BRAF mutations
cause constitutive activation of the MAPK pathway resulting in increased cell
proliferation and survival contributing to melanoma formation (Sumimoto et al.,
2006). Mutations in the NRAS oncogene, which are seen in 10-20% of melanomas,
also activate the MAPK pathway (Marks & Neill, 2008, p. 149). BRAF and NRAS
mutations are mutually exclusive suggesting they have similar roles in uncontrolled
melanocyte proliferation leading to melanoma development (Villanueva & Herlyn,
2009).
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2.4. Diagnosis and Treatment

Initial diagnosis of melanoma is made using the ABCDE system to determine
whether a lesion is likely to be a melanoma. Using this system, a lesion may be a
melanoma if it is asymmetrical, has an irregular border, uneven colouring, a diameter
greater than 6mm and is evolving or changing over time (Tan, 201 0) (Fig 2.3.). If a
lesion is diagnosed as a melanoma it will be surgically resected with surrounding
tissue in order to remove as many malignant cells as possible (Urist, 1996). The
amount of surrounding tissue excised is based on the thickness of the tumour (Jack
et al., 2006).

Figure 2.3. A typical example of superficial spreading melanoma depicting asymmetry, irregular
border and uneven colouring (Ada County, n.d.).

If the patient has metastatic disease at the time of removal of the primary tumou r
prognosis is less favourable (Wascher et al., 2003). Usually if the tumour is greater
than 0.75 millimetres in thickness or is ulcerated, the sentinel lymph node, which is
the first node to receive drainage from a primary tumour and the most common first
site of metastasis (Goto et al., 2008), will be examined for involvement and can be
surgically removed if there is evidence of metastasis. If the sentinel node is
metastatic, this process will be repeated in other regional nodes (Krag et al., 1995).
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Surgical removal of secondary tumours is regularly undertaken in patients where
metastasis is more distant than regional lymph nodes (Tan, 201 0). If metastasis is
extensive, chemotherapy, immunotherapy, interferon therapy or radiotherapy may be
considered although melanoma is notoriously resistant to these treatments. Of these,
the most successful therapies have proven to be immunotherapy with interleukin-2
and interferon therapy with interferon-alpha, however patient responses vary
considerably and the toxicity of these treatments is high (Steen et al., 2008). The
only chemotherapeutic agent currently approved for the treatment of metastatic
melanoma by the US Food and Drug Administration is dacarbazine, which is often
used in conjunction with other therapies (Biesa et al., 2009).

A number of targeted therapies have been trialed for use in the treatment of
metastatic melanoma in order to specifically inhibit melanoma growth with the intent
of increasing treatment efficacy while eluding the adverse effects of more general
cancer therapies. The use of mutant BRAF inhibitors showed particular promise in
this area (Shepherd et al., 201 0) although initial success of trials applying this
treatment have since been tempered by indications of resistance to this therapy
(Fisher et al., 201 0; Flaherty et al., 201 0; Modjtahedi & Essapen, 2009).

2.5. Staging

It is important to accurately stage melanoma in order to determine prognosis and
establish the best possible strategy for treating the disease. Staging of the disease is
based on thickness of the primary tumour, the presence of ulceration and the extent
of metastasis. The most widely used staging system for melanoma is that instigated
by the American Joint Committee on Cancer (AJCC). Stages range from 0 to 4,
where 0 describes a primary tumour in situ and 4 describes patients with extensive
metastasis. Within these stages there are many sub-stages describing primary
tumour thicknesses and specific sites and types of metastases; these are grouped
into stages 0, 1A, 1B, 2A, 28, 2C, 3 and 4 (American Joint Committee on Cancer,
2002) (Table 2.1.). Stage 1A melanoma is associated with a five-year survival rate of
95% whereas stage 4 melanoma is associated with a five-year survival rate of 7 to
19% depending on the number and location of metastases {Tan, 201 0). Stage 4
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patients can be further subdivided based on their serum lactate dehydrogenase
(LDH) level.

Table 2.1. The AJCC Staging System for Melanoma (adapted from American Joint
Committee on Cancer, 2002)
Description

Stage

0

Primary tumour in situ
Primary tumour less than or equal to 1mm in

1A

thickness with no ulceration and no evidence
of metastasis
Primary tumour less than 1mm in thickness
with ulceration but no evidence of metastasis

18

OR primary tumour between 1 and 2mm in
thickness with no ulceration and no evidence
of metastasis
Primary tumour between 1 and 2mm in
thickness with ulceration but no evidence of

2A

metastasis OR primary tumour between 2
and 4 mm in thickness with no ulceration and
no evidence of metastasis
Primary tumour between 2 and 4mm in
thickness with ulceration but no evidence of

28

metastasis OR primary tumour greater than
4mm in thickness with no ulceration and no
evidence of metastasis
Primary

2C

tumour

greater

than

4mm

in

thickness with ulceration but no evidence of
metastasis
Primary

3

tumour

any

thickness

with

metastasis to one or more regional lymph
nodes but no distant metastases
Primary tumour any thickness with distant

4

metastasis to skin, subcutaneous tissue,
lymph nodes, lungs and visceral organs
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The LDH test allows the extent of metastasis to be determined. The test measures
the level of serum lactate dehydrogenase (LDH) which increases in response to
tissue damage, especially to the heart, lungs, liver, kidneys, brain and skeletal
muscle resulting from invasion of tissues by metastatic tumours (Agarwala et al.,
2009). LDH level is currently the strongest independent prognostic factor in
advanced metastatic melanoma and therefore proves useful in the postoperative
monitoring of patients as it is a good predictor of survival (Utikal et al., 2007). If
serum LDH is elevated, the presence of metastases should be confirmed by CT,
PET or MRI scans as elevated LDH is not exclusive to metastatic melanoma and can
also result from muscle injury, liver disease and hypotension (Agarwala et al., 2009).
It has been found that although elevated serum LDH is strongly associated with poor
prognosis, there is a weak relationship between LDH level and tumour thickness. It is
also the case that elevated LDH is not associated with specific sites of metastasis
which shows that the LDH test should be performed irrespective of tumour size and
location of metastases.

2.6. Melanoma Markers

To further optimise melanoma staging, there has been much recent research aiming
to identify markers of disease progression. Current research is being undertakefl to
identify the expression of genes in metastatic cells which can be used to show
residual disease in clinically disease-free patients. This will provide prognostic
information in these patients revealing the likelihood of disease relapse (Hoon et al.,
2000). The problem is that as more studies are undertaken, evidence shows that
malignant melanoma is an extremely heterogeneous disease with patterns of gene
expression varying considerably between cases and between cells within the same
tumour (Hoon et al., 2000; Reynolds et al., 2003). However, although there is
considerable variation within the disease, some genes are seen to be abnormally
expressed in the majority of cases while others are implicated less frequently.
Research continues into developing a reliable set of markers for use in profiling of
the disease.
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Other research has set out to establish which markers are associated with an
aggressive phenotype with high metastatic potential as opposed to a less aggressive
phenotype with low metastatic potential (Bittner et al., 2000; Ryu et al., 2007).
Identification of these markers would allow the prognosis of early primary tumours to
be evaluated independent of tumour thickness and before metastasis has occurred.
Results to date have shown that the expression levels of many genes are altered in
cells categorised as more aggressive compared with less aggressive cells. Many
genes involved in cell cycle control, cell proliferation, DNA replication and repair and
resistance to apoptosis are upregulated in more aggressive cells while many genes
involved in cell adhesion and melanocyte differentiation are downregulated (Ryu et
al., 2007). Unfortunately, results of these studies have been inconclusive due to the
abundance of associated markers which vary considerably between cases resulting
in a number of different phenotypes being associated with tumour aggressiveness
(Seftor et al., 2002). It is also unclear whether primary tumour cells that appear to
have an aggressive phenotype are the same cells responsible for the formation of
secondary tumours in metastatic disease.

.I

2.6.1. Types of Markers

Research has found an abundance of markers associated with melanoma.

Thes~

markers may be normal melanocyte genes involved with normal melanocyte
function, markers specific to melanoma which are not expressed in normal
melanocytes or other tumours or non-specific markers involved with tumour growth
and development which are expressed in a variety of cancer types (Medic et al.,
2006). As previously mentioned, due to the heterogeneous nature of melanoma
there are many markers associated with the disease with some being expressed
more frequently than others. ·For this reason, only those markers detected in a large
percentage of melanomas showing the greatest promise for use in improving
diagnostic and prognostic techniques will be discussed.
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2.6.1.1. Normal Melanocyte Markers

There are a number of markers associated with melanoma that are expressed in
both normal melanocytes and melanoma cells. Tyrosinase is an enzyme involved in
the production of melanin which is commonly used as a marker in melanoma
diagnosis and prognosis (Osella-Abate et al., 2003; Proebstle et al., 2000; Schmidt
et al., 2005). Although tyrosinase is expressed in normal melanocytes, its detection
in patient blood suggests the presence of melanoma cells as normal melanocytes do
not enter the circulatory system (Steen et al., 2008).

Microphthalmia-Associated

Transcription

Factor

(MITF)

is

involved

in

the

differentiation of melanocytes during melanocytic development (Loercher et al.,
2005). It is also implicated in the proliferation and development of invasive behaviour
of melanoma cells (Carreira et al., 2006; Garraway et al., 2005). Due to its role as a
transcription factor, MITF regulates the expression of many other melanoma
'

associated genes, such as MART-1 (Duet al., 2003).

Tyrosinase-Related Protein-1 (TYRP-1) and Tyrosinase-Related Protein-2 (TYRP-2)
are both expressed in normal melanocytes and are involved in melanin synthesis
(Urabe et al., 1993). These genes are also expressed in melanoma cells however
their expression only provides prognostic information in more advanced stages of the

I

disease (Takeuchi et al., 2004).

2.6.1.2. General Tumour Markers

A number of markers associated with melanoma are non-specific tumour markers
expressed in a range of malignancies. Melanoma antigen gene A3 (MAGE-A3) is
expressed in a variety of cancers including testicular cancer and melanoma,
however it is not expressed in normal tissue with the exception of some reproductive
cells such as male gametes and cells of the placenta (Koyanagi et al., 2005a). In
melanoma, MAGE-A3 is more commonly expressed in early stages of the disease
(Hoon et al., 2000; Koyanagi et al., 2005a).
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S100 is a group of genes expressed in cells of neural crest origin and several S100
genes are expressed in neural crest derived tumours, which include melanoma
(Schmidt et al., 2005). S100p is one S100 marker commonly used to detect
metastasis in sentinel lymph nodes of melanoma patients (Goto et al., 2008). S100b
is another S1 00 gene which is not frequently detected in early stage melanomas but
is commonly detected in later stages of the disease where it corresponds with
prognosis (Martenson et al., 2001 ).

2.6.1.3. Melanoma Specific Markers

Other markers are specific melanoma associated antigens which allow the
differentiation of melanomas from other cutaneous malignancies. Melanoma Antigen
Recognised by T cells-1 (MART-1 ), which also has the synonyms MLANA and
Melan-A, is involved in the formation of melanosomes which are the melanin storing
organelles contained in melanocytes (Du et al., 2003). MART-1 can be detected in
peripheral blood of advanced stage patients suggesting its expression is related to
disease progression and may be useful in predicting patient survival (Koyanagi et al.,
2005a,b).

Melanoma-Associated Chondroitin Sulphate Proteoglycan (MCSP), also known as
High-Molecular Weight Melanoma-Associated Antigen (HMW-MAA), is encoded by

j

the CSPG4 gene (Wang et al., 2004). MCSP is expressed on the surface of
melanoma cells and is implicated in cell adhesion, proliferation, migration and
invasion (Yang et al., 2004; Yang et al., 2009). MCSP is uniformly and abundantly
expressed in the majority of melanomas (Yang et al., 2004). It can further be
detected in early metastatic cells during subcutaneous invasion (Wang et al., 2004)
and is therefore a useful marker to target for detection of early metastasis. A study
by Goto et al. (2008) showed that all sentinel lymph nodes in metastatic melanoma
patients were positive for MCSP by immunohistochemical staining with MCSP
antibody. The results also showed that MCSP was more specific and sensitive than
MART-1 and S100p for detecting sentinel lymph node metastasis, both of which are
commonly used for this purpose. Other research has shown MCSP is expressed on
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the surface of circulating melanoma cells as circulating cells have been successfully
captured using anti-MCSP bound immunomagnetic beads (Kitago et al. 2009; Ulmer
et al., 2004 ).

Melanoma Cell Adhesion Molecule (MCAM), also known as MUC-18 and CD146, is
a cell surface melanoma marker encoded by the MCAM gene (Wang et al., 2004 ).
The sequence of MCAM is similar to the neural cell adhesion molecules of the
immunoglobulin

superfamily,

which

are

involved

in

organogenesis

during

development (Lehmann et al., 1989). This suggests that MCAM is normally involved
in intercellular adhesion and may also be developmentally regulated. It has been
observed that MCAM is downregulated in normal melanocytes and the majority of
early melanomas probably due to cell-cell contact with neighbouring keratinocytes
(Shih et al., 1994). Low level expression is seen in early melanomas, which is
thought to be due to escaped control of keratinocytes, and high level expression is
observed in late stage melanomas due to constitutive activation of the MCAM gene.
MCAM is constitutively expressed in 70% of metastatic melanomas with amplified
expression associated with increased tumour thickness and aggressive invasive
behaviour (Mangahas et al., 2004; Medic & Ziman, 201 0). Studies have shown
MCAM is frequently detected in multi-marker qRT-PCR assays of patient peripheral
blood and its expression is strongly related to disease progression (Hoon et al.,
2000).

2. 7. Melanoma Stem Cells

Recent research has identified melanoma stem cells capable of self renewal and
differentiation which may lead to tumourigenesis (Boiko et al., 201 0; Sekulic et al.,
2008). It is thought that proliferation of these highly resistant cells after treatment
may result in disease relapse (Fig 2.4.). Similar cells have been identified in other
malignancies and it is thought they may play a significant role in tumour maintenance
in those tumours which are notoriously difficult to treat. It has been observed that
normal stem cells show a great deal more resistance to toxic treatments such as
chemotherapy and radiotherapy than their differentiated descendants (Sekulic et al.,
2008). The idea that melanomas arise from tumorigenic stem cells is further hinted at

13

by the heterogenic nature of the disease which suggests tumours originate from cells
capable of multi-lineage differentiation (Fang et al., 2005).

Melanoma stem cell

Selfrenewal

!

Tumor growth

Daughter cell death

!
Melanoma stem cell
survives

!
Tumor relapse with
new daughter cells

Figure 2.4. The proposed capability of melanoma stem cells for tumour maintenance and renewal
(Sekulic et al., 2008)

A sub-population of melanoma stem cells express ATP-Binding Cassette Subfamily
B Member 5 (ABCB5) on their surface. ABCB5 is actively involved in removing toxic
substances, such as chemotherapeutic agents, from these cells (Chen et al., 2005).
It has been shown that ABCB5 positive cells have greater tumourigenic capacity as
well as a greater ability for renewal and differentiation than ABCB5 negative cells.
The possible role of ABCB5 positive stem cells in tumour growth was shown by
Schatton et al. (2008) who demonstrated inhibited tumour growth in mice that
underwent treatment targeting ABCB5 positive cells. If the role of these stem cells in
tumour formation is established and their presence among circulating cells is
confirmed, approaches to treatment would be significantly influenced as these highly
resistant cells would need to be targeted concurrently with the general tumour cell
population in order to reduce the chance of disease relapse .
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2.8. Circulating Tumour Cells

More recently, research has been conducted to measure markers of circulating
melanoma cells in patient blood. The rationale of this is that previous studies have
shown circulating tumour cells are often present in the circulation of cancer patients
and are associated with tumour progression (Steen et al., 2008). It is estimated that
on average, tumour cells circulate in the blood at a concentration of one per 106 to
107 normal cells (Krivacic et al., 2004). Due to the ability of circulating tumour cells to
form metastases, their detection may identify patients with a greater risk of disease
relapse significantly earlier than methodologies for the detection of secondary
tumours or residual disease, which is currently undetectable at early stages
(Reynolds et al., 2003). Because of this, it is thought that circulating melanoma cells
may be a good measure of prognosis and may be able to guide treatment of the
disease (Hoon et al., 2000; Steen et al., 2008; Ulmer et al., 2004). Current
prognostic techniques, including measuring primary tumour thickness and sentinel
lymph node examination, are unable to adequately guide treatment and it is thought
that the detection of circulating melanoma cells may provide information that can be
monitored

to

establish

treatment

strategies

and

determine

their

efficacy.

Furthermore, these prognostic tests are unable to identify many early stage patients
requiring treatment as a significant number of non-metastatic patients who are
clinically disease free following surgery later develop metastatic disease. It has bee·n
suggested that approximately 30% of in situ patients (Koyanagi et al., 2005a) and
15% of patients with no evidence of lymph node metastasis (Jack et al., 2006;

)

Weight et al., 2006) at the time of surgical intervention subsequently develop
metastases. Quantifying circulating cells in early stage patients may therefore be
useful in identifying those patients at risk of disease relapse who may benefit from
some form of treatment.

2.8.1. qRT-PCR Detection of Markers

Early methods of detecting circulating tumour cells in patient blood involved the
automated scanning of blood samples in order to identify labelled cells, however
these methods were extremely time consuming. Quantitative Real-Time Polymerase

15

Chain Reaction (qRT-PCR) has allowed marker mRNA transcripts in circulating
melanoma cells to be detected in patient peripheral blood samples suggesting the
presence of circulating melanoma cells (Arenberger et al., 2008; Hoon et al., 1995;
Hoon et al., 2000; Koyanagi et al., 2005a; Lewis et al., 2005; Reynolds et al. 2003).
This technique can detect markers in extremely small quantities and far more rapidly
than previous methods due to its sensitivity and efficiency. It has been shown that
qRT-PCR can detect RNA from one malignant cell in 10A7 normal background cells
which is sufficiently sensitive to detect low numbers of circulating tumour cells (Lewis
et al., 2005). Furthermore, many studies have detected markers in peripheral blood
of AJCC stage I and II patients who have no evidence of metastasis, suggesting the
presence of circulating melanoma cells even in early stages of the disease (Hoon et
al., 1995; Hoon et al., 2000; Koyanagi et al., 2005a).

It has been shown that circulating tumour cells can be detected in patient peripheral
blood using a single marker qRT-PCR assay (Proebstle et al., 2000; Stoitchkov et
al., 2001 ), although more recent studies have aimed to develop a suitable multimarker assay to increase the sensitivity of the test and thus increase rates of
detection. The reason for the requirement of a multi-marker assay is due to the
heterogeneous nature of melanoma, which causes variability of marker expression
between cells meaning not all cells will be detected by RT-PCR of a single mRNA
transcript (Hoon et al., 2000). Studies employing multi-marker qRT-PCR assays
have shown they offer a higher detection rate than single marker assays (Hoon et
al., 1995; Koyanagi et al., 2005a; Reynolds et al. 2003), however a standard multi/marker assay has yet to be developed.

Research has shown, however, that there are many limitations to this technique. Due
to the heterogeneous nature of melanoma, marker expression can vary considerably
between patients and even within the same patient (Steen et al., 2008) resulting in
the possibility of false negatives as the genes being targeted may not be expressed
or may not be undergoing transcription at the time blood is obtained. One particular
study showed that patients may be positive or negative for certain melanoma
markers at different times of the day depending on the time blood samples were
taken (Keilholz et al., 2004 ). Some studies have also reported a number of false
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positives where control blood samples appear positive for particular melanoma
markers. This could be due to inadequate specificity of the test, epithelial cell
contamination of blood samples or simple issues of quality control (Steen et al.,
2008). In addition to specificity issues, some studies have shown this technique to be
inadequately sensitive, reporting detection of markers by qRT-PCR in fewer than
50% of stage IV patients with advanced metastatic disease (Mocellin et al., 2004).

2.8.2. Circulating Cells: Quantity vs. Phenotype

Although qRT-PCR shows circulating cells are present in patient blood, via the
detection of melanoma markers, it does not allow them to be quantified. A suitable
method allowing the quantification of circulating cells in patients at different clinical
stages of melanoma would be valuable as it will help to reveal the relationship
between CTC numbers and disease prognosis. At this point in time the influence of
quantity and phenotype of circulating cells on prognosis is largely unknown with
current research producing conflicting evidence. Some studies have shown that an
increase in circulating cell numbers appears to correlate negatively with survival
(Steen et al., 2008; Ulmer et al., 2004); although these studies are far from definitive
as circulating cells were unable to be captured in many patients tested. Furthermore,
some evidence suggests cells with tumourigenic potential, based on their phenotype,
are rare (Boiko et al., 201 0), whereas others argue that the majority of melanoma
cells may be capable of tumour formation (Quintana et al., 2008). If an increase in
circulating cell numbers is found to correlate with more advanced disease stage,
circulating cell numbers could be used as a measure of disease progression to
)prove prognostic testing.
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2.9. lmmunomagnetic Bead Capture

Currently, immunomagnetic bead capture is one of the most promising methods of
isolating circulating tumour cells from patient peripheral blood samples (Steen et al.,
2008). lmmunomagnetic beads, when coupled with antibody, allow for the isolation
of specific cells within a sample as the antibody-bead ligand is allowed to bind to the
cell type of interest which can then be isolated from the sample with the use of a
magnet (Fig 2.5.).

Figure 2.5. The principle of isolating CTCs through immunomagnetic enrichment. (Adnagen, n.d .)
Magnetic beads are coupled with antibody which bind CTCs in patient peripheral blood. CTCs
can subsequently be isolated from the sample using a magnet.

A number of studies have provided evidence showing isolation of melanoma cells
from patient peripheral blood via immunomagnetic bead capture is successful (Faye
et al., 2004; Kitago et al. 2009; Ulmer et al., 2004). In order for immunomagnetic
beads to capture circulating tumour cells they must be able to bind a minimum of one
cell per 106 background cells otherwise low numbers of circulating cells would not be
able to be captured (Krivacic et al., 2004). The results of blood spiking experiments,
where single melanoma cells have been added to control blood samples to
demonstrate the detection limit of antibody-coupled beads, have shown that these
beads are sensitive enough to bind low concentrations of circulating tumour cells.
For example, a study by Faye et al. (2004) showed that anti-MCSP coupled
immunomagnetic beads were able to bind a single melanoma cell in a sample
containing 107 normal blood cells. A similar spiking experiment by Kitago et al.
(2009) demonstrated their anti-MCSP beads were able to bind one melanoma cell in
5x1 0"6 blood cells. These results show that immunomagnetic bead capture is a
sensitive enough method to isolate low quantities of circulating melanoma cells.
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The CeiiSearch system uses EpCAM antibody bound immunomagnetic beads to
isolate circulating tumour cells in a number of malignancies of epithelial origin (Steen
et al., 2008). This system has been used successfully to isolate circulating cells from
peripheral blood in breast cancer patients and was tested in stage Ill and IV
melanoma patients as circulating melanoma cells are known to be positive for
EpCAM. The results showed that circulating cell numbers appeared to correlate with
survival as an increased number of circulating cells was associated with a decreased
survival time. However, the anti-EpCAM beads were only able to capture circulating
cells in some of the stage IV patients included in the study. As the marker used in
this assay is not melanoma specific, the use of immunomagnetic beads bound to
melanoma specific antibodies may be more successful.

Studies trialling immunomagnetic bead capture of circulating melanoma cells with
anti-MCSP coupled beads have provided mixed results. One study was able to
isolate circulating melanoma cells from 100% of stage IV patients tested (Kitago et
al.,' 2009), while another was only able to detect circulating cells in 1% of patients
ranging from stage I to IV; however this study defined captured cells as those bound
to more than four beads which were detected by microscopy (Faye et al., 2004). A
study by Ulmer et al. (2004) was able to isolate cells from patients of all AJCC
stages with anti-MCSP beads, although cells were not detected in all patients; only
43% of stage IV patients were positive for circulating cells. Also, the number of cells
captured in patients of each stage varied widely with considerable overlap, possibly
due to heterogeneous expression, suggesting a combination of antibodies would be
more effective at capturing cells. Since previous results have only been somewhat
successful, different combinations of antibodies should be trialled to optimally
capture circulating melanoma cells in patients at all stages of the disease in order to
show the difference in quantity and phenotype of early and late stage cells.
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2.9.1. Suitable Target Antigens

Due to the mixed success when a single marker was targeted in previous bead
capture studies, as well as the fact that melanoma is extremely heterogeneous, a
combination of antibodies was used in this study in order to maximise the chances of
successfully isolating circulating melanoma cells in patients' at all stages of the
disease. For an antibody to be suitable for capturing circulating cells it must have a
number of characteristics. Firstly, the marker for which the antibody is specific must
be expressed on the surface of melanoma cells. This is to ensure the antibody can
recognise and bind to the marker which would not be possible if it was expressed
within the cell. Antibodies should also target markers which are expressed in the
majority of cells to ensure all circulating cells are captured when used in combination
with other antibodies.

MCAM is constitutively expressed on the surface of the majority of advanced stage
,

melanoma cells and its expression is strongly related to disease progression
(Mangahas et al., 2004; Medic & Ziman, 2010; Shih et al., 1994). For this reason,
MCAM is a suitable marker to target for the isolation of circulating melanoma cells in
patients of more advanced stages of the disease. The fact that MCAM expression is
associated with aggressive tumour behaviour also suggests that it is a suitable
marker to target for the isolation of aggressive cells with high metastatic potential.

MCSP is expressed on the surface of early stage melanoma cells (Wang et al.,
2004; Yang et al., 2004) and its expression continues throughout all stages of the
disease (Faye et al., 2004; Goto et al., 2008; Kitago et al., 2009; Ulmer et al., 2004).
MCSP is therefore a suitable cell surface marker to target for the isolation of early
stage circulating cells as well as more advanced stage cells which do not express
MCAM and therefore may have a less aggressive phenotype. As previously
discussed, it has been suggested that although stage I and II patients do not have
metastatic disease they may still have circulating tumour cells as peripheral blood of
these patients has been shown to be positive for a number of melanoma markers by
qRT-PCR (Hoon et al., 1995; Hoon et al., 2000; Koyanagi et al., 2005a).
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Lastly, ABCB5 is expressed on the surface of a subset of melanoma stem cells
which have greater tumourigenic capability than ABCB5 negative melanoma stem
cells (Chen et al., 2005). ABCB5 antibody can therefore be used to isolate circulating
ABCB5 positive melanoma stem cells which are thought to be implicated in disease
relapse following treatment (Chen et al., 2005; Sekulic et al., 2008). Currently, no
studies have shown melanoma stem cells in patient circulation although unpublished
results from our laboratory have shown many patient blood samples are positive for
ABCB5 by qRT-PCR.

2.9.2. lmmunomagnetic Bead Capture in other Malignancies

The use of immunomagnetic bead capture to isolate circulating tumour cells in other
malignancies, including those of the prostate and colon, has been investigated for
some time. This technique is most commonly used however, and has provided the
most success, in breast cancer patients. Many studies have provided evidence that
this method is successful and have shown that the presence of circulating cells
correlates with poor prognosis (Austrup et al., 2000; Cristofanilli et al., 2004; Raynor
et al., 2009; Tewes et al., 2009). The use of this technique in breast cancer patients
has proven to be both more sensitive and specific at detecting circulating cells than
qRT-PCR (Bossolasco et al., 2002; Martin et al., 2001; Witzig et al., 2002) and
metastatic cells circulating at 1 in 106 -10 7 background cells can be consistently
captured

(Reuben et al., 2008). A study by Raynor et al.

(2009) used

immunomagnetic bead capture to isolate circulating cells from patient blood and
subsequently used a multi-marker qRT-PCR assay on isolated cell RNA to detect
tumour associated markers. The results of this study showed the number of patients
positive for at least one marker increased with both disease stage and primary
tumour thickness. Another. study showed that patients positive for circulating cells
had shorter overall survival than those classified as negative, where a patient was
considered positive if they had five or more circulating cells per 7 .5ml of blood
(Cristofanilli et al., 2004). Quantification of circulating cells has also shown success
at monitoring patient responses to treatment; specifically an increase in circulating
cells at treatment completion predicts early relapse of the disease (Lobodasch et al.,
2007; Pachmann et al., 2008; Pachmann et al., 2005).
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The success of this method has led to its clinical use with the CeiiSearch system
being approved by the US Food and Drug Administration for the detection of
circulating cells in patients with metastatic carcinoma of the breast (Reuben et al.,
2008). The reason for the greater success of this technique in breast cancer patients
compared with melanoma patients is likely due to the trialling of different
combinations of antibodies to capture circulating cells which has led to the
development of many breast cancer tests, such as the AdnaTest (Adnagen), which
target a combination of cell surface markers. Studies trialling this technique in
melanoma patients have targeted single markers only going as far as testing a
combination of clones of an antibody to isolate circulating cells (Kitago et al. 2009).
Both carcinoma of the breast and melanoma are heterogeneous and for this reason
the use of multiple antibodies proposed in this study may increase the success of
this technique in melanoma.

Overall, the use of this technique in breast cancer patients has demonstrated
circulating cells are an independent predictor of survival of greater value than
standard prognostic measures (Reuben et al., 2008). This shows that isolation of
circulating cells by immunomagnetic bead capture is useful for determining patient
prognosis and with further investigation this technique has the potential to be
similarly applied in the clinical testing of melanoma patients.
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3. Summary and Theoretical Framework

The development of an immunomagnetic bead capture assay using antibodies able
to effectively bind melanoma cells of all disease stages will provide a suitable
method of isolating circulating melanoma cells. This technique will have advantages
over the use of RT-PCR, which can only detect the presence of circulating cells, by
allowing circulating cells to be captured and quantified. This will reveal the prognostic
significance of circulating cell numbers which has not yet been determined. If it is
found that circulating cell numbers correlate strongly with prognosis, i.e. circulating
cell numbers increase with increased disease stage, this technique could be used
routinely as a prognostic measure in combination with other available measures,
such as primary tumour thickness. If this is the case, quantification of circulating cells
could also be used as a measure of treatment efficacy. For example, the number of
circulating melanoma cells in a patient undergoing therapy could be continually
measured to determine whether the treatment is effective, i.e. whether it is reducing
the number of circulating cells. This would allow the effectiveness of multiple
treatments on individual patients to be determined.

As well as the quantification of circulating cells, this technique would allow
phenotypic analysis of captured cells to be performed in further studies in order to
characterise circulating cells of different disease stages. This would allow phenotypic
differences between early and late stage cells to be determined, ultimately revealing
the influence of circulating cell phenotype on prognosis.

In this study, MCSP, MCAM and ABCB5 antibody coupled immunomagnetic beads
were used to isolate and subsequently quantify circulating melanoma cells from
patient peripheral blood samples across all disease stages in order to determine a
relationship between the number of circulating cells and disease stage.
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4. Hypothesis and Aims

4.1. Hypothesis

The number of circulating melanoma cells in patient peripheral blood correlates with
disease stage.

4.2. Aims

The overall aim of this research project is to isolate and quantify circulating
melanoma cells in patient peripheral blood in order to determine the relationship
between the number of CTCs and disease stage. This will be achieved by:

1) Checking for marker expression in melanoma cell line and tissue sections of
pifferent stages to determine the suitability of chosen antibodies to isolate
circulating melanoma cells.

2) Manufacturing and testing MCSP, MCAM and ABCB5 antibody coupled
immunomagnetic beads.

3) Isolating circulating melanoma cells from patient peripheral blood samples.

4) Quantifying total circulating cells relative to disease stage.
5) Quantifying MCSP, MCAM and ABCB5 positive circulating cells relative to
disease stage.
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5. Materials and Methods

5.1. Antibodies

5.1.1. MCAM

The MCAM antibody used for cell immunofluorescence and immunomagnetic
bead coupling was mouse monoclonal anti-human CD146, isotype lgG1 kappa,
at a concentration of 0.5mg/ml, sourced from BD Biosciences (San Diego, USA).
The

MCAM antibody used for tissue

immunohistochemistry was

rabbit

monoclonal anti-human CD146, isotype lgG, sourced from Abeam (Cambridge,
USA).

5.1.2. MCSP

The

anti-MCSP

antibody

immunohistochemistry

and

used

for

cell

immunomagnetic

immunohistochemistry,
bead

coupling

was

tissue
mouse

monoclonal anti-human MCSP clone number 9.2.27, isotype 1Gg2a, at a
concentration of 0.5mg/ml, sourced from BD Biosciences.

5.1.3. ABCB5

The anti-ABCB5 antibody used for immunomagnetic bead coupling was rabbit
polyclonal anti-human ABCB5 at a concentration of 0.31mg/ml, sourced from
Rockland lmmunochemicals. The anti-ABCB5 antibody used for flow-cytometry
was mouse monoclonal anti-human ABCB5, clone number 3C21 012, received
from Markus Frank, Brigham and Women's Hospital, Harvard Medical School
(Boston, USA).
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5.2. Cell lines

The A2058 melanoma cell line was used to demonstrate marker expression in
melanoma cells as well as for experimental testing of antibody-coupled
immunomagnetic beads. This highly invasive malignant melanoma cell line was
established from a lymph node metastasis of a 43 year old male. HEK293 cells
(Human Embryonic Kidney 293 cells) were used as a negative control in the
testing of marker expression and antibody-coupled beads.

5.3. Blood Samples

5.3. 1. Patient Samples

This study was conducted according to the National Statement on Ethical
,Conduct in Research Involving Humans, approved by the Edith Cowan University
Human Research Ethics Committee. Patients with clinical disease stages 0 - IV
were recruited by five Perth based clinicians. Six stage 0 patients, ten stage I
patients, eight stage II patients, three stage Ill patients and six stage IV patients
were included in the study. Patients were diagnosed and staged based on clinical
and pathological data using the AJCC staging system for melanoma (Table 2.1 ).
Patients with metastatic disease were treated as per standard clinical protocols.
Participants signed informed consent with the clinician in accordance with
protocols safeguarding patient rights and were provided with a clinical trial form
for blood collection. Approximately 4ml of blood was drawn by phlebotomists into
EDTA tubes, stored refrigerated at pathology centres and collected when
possible. A clinical registrar recorded patient clinical data in an excel spreadsheet
kept separate from laboratory results.

5.3.2. Control Samples

Control blood for use in experimental testing of immunomagnetic beads was my
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own or sourced from volunteers and was drawn by a phlebotomist into EDTA
tubes and used immediately. There were 21 control blood samples used for
comparison with patient samples, which were obtained from healthy volunteers
with no previous history of melanoma and drawn by a phlebotomist into EDTA
tubes and processed within a few hours. The first few millilitres of all blood
samples collected for this study were discarded in order to avoid epithelial cell
contamination.

5.4. Marker Expression in A2058 Melanoma Cell Line

The expression of MCAM and

MCSP in A2058 melanoma cells was

demonstrated by immunofluorescence. A2058 cells and HEK293 cells, to be
used as a negative control, were plated onto sterile coverslips at a density of
5x1 04 cells per coverslip and allowed to adhere overnight. The media was
removed by aspiration and the coverslips were washed in PBS. The PBS was
then aspirated and the cells were fixed by a 10 minute room temperature
incubation in 4% paraformaldehyde. The cells were washed twice with PBS and
permeabilised by incubation in 0.2% Triton X-100 in PBS for 5 minutes at room
temperature. The coverslips were then washed three times in 0.2% Triton X-100
in PBS over 5 minutes.

The coverslips were incubated at room temperature for 60 minutes with the
primary antibody solution. Antibodies were diluted 1 in 500 in 0.2% Triton X-100
in PBS containing 3% BSA. The coverslips were then washed three times in
0.2% Triton X-100 in PBS over 5 minutes. They were then incubated at room
temperature for 20 minutes with the secondary antibody (anti-mouse lgG
conjugated to Alexa Fluor 488), also diluted 1 in 500 in 0.2% Triton X-1 00 in PBS
containing 3% BSA. Coverslips were again washed three times in 0.2% Triton X100 in PBS over 5 minutes, drained well and placed onto a drop of mounting
medium (Prolong Gold antifade reagent, containing DAPI for nuclear staining
from Invitrogen (Oslo, Norway)) on a microscope slide. The slides were allowed
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to air dry before viewing by fluorescence microscopy with an epifluorescent
Olympus BX51
microscope equipped with an Olympus DP71 camera.

The demonstration of ABCB5 expression in these cells was attempted using the
above protocol however staining was negative raising questions regarding the
suitability of this particular ABCB5 antibody for immunofluorescence. Instead,
flow-cytometry was used in order to demonstrate ABCB5 expression in A2058
cells.

5.5. Flow Cytometry

A2058 cells were harvested with media containing EDTA (2mM EDTA in DMEM
media) and resuspended in 1Om I of DMEM media containing 10% FBS. 0.5ml
was counted on the Vi-Ceii-XR Cell Viability Analyser (Beckman Coulter, Brea,
USA) and the appropriate volume containing approximately 500,000 cells was
dispensed into each of 4 tubes. The cells were pelleted at 2000rpm for 5 minutes
and the media was removed. The pellets were washed in 500!-11 of MACS buffer
(2mM EDTA, 0.5% BSA in PBS, pH 7.2) (Miltenyi, Bergisch Gladbach,
Germany), pelleted again and the supernatants were aspirated to remove any
remaining media. The pellets were then resuspended in 5001JI of MACS buffer.
Two tubes were incubated with primary antibody, one with ABCB5 antibody
(1/500) and another with MCSP antibody conjugated toPE (1/500), for 20
minutes at room temperature. The cells were then pelleted, the supernatant was
aspirated and the pellet was resuspended in 5001JI of MACS buffer. The tube
containing ABCB5 antibody and one tube without a primary were both incubated
with secondary antibody (anti-mouse lgG conjugated to Alexa Fluor 488) for 20
minutes at room temperature. The tubes were then centrifuged at 2000rpm for 5
minutes, the supernatant was removed and the pellets were resuspended in
5001JI of MACS buffer. These samples were then run on a Gallios Flow
Cytometer (Beckman Coulter). Cells were separated by side and forward scatter
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and antibody staining was detected by analysis of fluorescence emission of cells
where positive cells had increased fluorescence as a result of antibody
conjugated fluorochromes.

5.6. Marker Expression in Paraffin Embedded Melanoma Tissue Sections

The expression of MCSP and MCAM in sections of early and late stage
melanoma tissue was demonstrated by immunofluorescence. Three sections
each of in situ, invasive primary and metastatic melanomas were stained with
MCSP and MCAM antibodies in order to determine the extent of expression of
these genes in different stages of the disease. Demonstration of ABCB5
expression was not attempted in tissue sections due to the extremely limited
quantity of antibody available and the inability to demonstrate ABCB5 expression
in A2058 cells by immunofluorescence.

5.6.1. MCAM Staining

Paraffin embedded tissue sections on glass slides were dewaxed by incubation
at 58°C for 20 minutes followed by a series of wash steps through xylene,
ethanol and distilled water. Antigen retrieval was performed with EDTA/Tris
buffer, pH 8.0, by three 5 minute cycles in a microwave set at 50% power
(approximately 750 watts). Slides were then cooled in a cold water bath for 20
minutes, briefly dried and marked with a pap pen. Slides were then washed with
PBS three times for 5 minutes. Protein blocking was performed by 1 hour
incubation at room temperature with 10% normal goat serum (NGS) in PBST
(0.2% Triton X-100 in PBS, pH7.4). The protein blocking solution was poured off
and the slides were then incubated with primary antibody solution (rabbit antihuman MCAM diluted 1 in 500 in PBST containing 1% NGS) for 1 hour at room
temperature. Following this, slides were kept overnight in PBS at 4°C.

Slides were allowed to reach room temperature and were washed with PBS three
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times for 5 minutes. Sections were then incubated with secondary antibody
solution (anti-rabbit lgG conjugated to Alexa Fluor 488 diluted 1 in 500 in PBST
containing 1% NGS and Hoechst 1 in 50,000) for 1 hour at room temperature.
PBS was pipetted onto the slides to remove the antibody solution and slides
were subsequently washed in PBS for 1 hour, changing the PBS every 10
minutes. Slides were then mounted while still wet with a drop of Fluorsave
Reagent (Calbiochem, San Diego, USA) and were allowed to dry before viewing
by fluorescence microscopy with a drop of Prolong Gold anti-fade reagent
containing DAPI (Invitrogen), as described in 5.8.This method was previously
described in Medic and Ziman (2010).

5.6.2. MCSP Staining

The above method proved unsatisfactory for MCSP staining so a suitable
'protocol was optimised specifically for this antibody. Optimal results for MCSP
staining were achieved by following the same protocol as described in 5.6.1.,
although primary antibody concentration and incubation time was altered.
Primary antibody (mouse anti-human MCSP) was diluted 1 in 20, in PBST
containing 1% NGS and incubated overnight at 4°C. The remaining portion of the
protocol was identical to that described in 5.6.1.

For both MCAM and MCSP staining, positive and negative controls were used to
confirm positive staining within tissue sections. Paraffin-embedded A2058 cells
were used as a positive control and sections stained with secondary antibody
only were used as negative controls.

5. 7. Antibody-Bead Coupling

MCAM, MCSP and ABCB5 antibodies were bound to immunomagnetic beads
using the Dynabeads Antibody Coupling Kit (Invitrogen). This kit contained
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Dynabeads M-270 Epoxy beads, coupling solutions ('C1' and 'C2'), wash buffers
('LB' and 'HB') and storage buffer ('SB').

It was decided to use 101Jg of antibody per mg of beads for optimal antibodybead coupling, based on manufacturer's suggestions. Three volumes of
Dynabead M-270 Epoxy beads were weighed out, one for each antibody, and
were washed by vortexing in 1ml of C1 solution. The washed beads were then
collected by a magnet and the supernatant was removed. The appropriate
volumes of C1, as indicated in the kit instructions, were added to the beads along
with the corresponding volumes of each antibody and the resulting solutions
were mixed by vortexing. The appropriate volumes of C2 were added and the
solutions were again mixed by vortexing. The antibody-bead solutions were
incubated on a roller at 37°C overnight to allow binding. The antibody coupled
beads were collected on a magnet and the supernatant was removed. The beads
~hen

underwent a series of washes described in the manufacturer's instructions

and were finally resuspended in storage buffer and stored at 4°C until use.

5.8. Testing Antibody-Coupled Beads on A2058 Cells

A2058 cells were harvested with accutase and resuspended in 1OmI DMEM
media containing 10% FBS. 0.5ml was counted on the Vi-Ceii-XR Cell Viability
Analyser

(Beckman

Coulter)

and

the

appropriate

volume

containing

approximately 500,000 cells was added to each of 3 tubes. 11-11 of beads was
added to each tube, one bead type per tube, and tubes were then incubated for
30 minutes at 4°C on a roller to allow binding. Tubes were placed on a magnet to
collect the bead bound cells and the supernatant was removed. The beads were
washed 3 times in 1ml MACS buffer (2mM EDTA, 0.5% BSA in PBS, pH 7.2),
resuspended in 1001-JI MACS buffer and pi petted onto coverslips on a magnet.
The liquid was aspirated and the coverslips were allowed to dry before being
mounted onto microscope slides with a drop of Prolong Gold anti-fade reagent
containing DAPI (Invitrogen).
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5.9. Bead Capacity

A2058 and HEK293 cells were harvested with accutase and counted on the ViCeii-XR Cell Viability Analyser (Beckman Coulter). The volume containing
approximately 500,000 cells was calculated for each cell type and added to 6
tubes, 3 containing A2058 cells and 3 containing HEK293 cells. The cells were
pelleted at 2000rpm for 5 minutes, the supernatants were removed and the
pellets were washed in 1ml MACS buffer (2mM EDTA, 0.5% BSA in PBS, pH
7.2). The solutions were then centrifuged again, the supernatants were discarded
and the pellets were resuspended in 1ml MACS buffer. 11JI of beads was then
added to each tube, each bead type being added to one tube of A2058 and one
tube of HEK293 cells. The tubes were then incubated on a roller for 30 minutes
at 4°C.

' Tubes were placed on a magnet to collect the beads and washed 5 times with
MACS buffer. The beads were resuspended in 1ml MACS buffer and were
analysed on the Vi-Ceii-XR Cell Viability Analyser in order to count the number of
cells bound to the beads.

5.1 0. Preliminary Patient Test

Red blood cell (RBC) lysis buffer (140mM NH4CI, 17mM Tris, pH 7.65) was
added to a patient blood sample to a total volume of 50ml and incubated at 37°C
until the solution became clear, indicating complete lysis. The solution was
centrifuged at 300g for 5 minutes at 4°C and the supernatant was discarded. The
pellet was washed in RBC lysis buffer, centrifuged again, the supernatant was
discarded and the pellet was resuspended in 3ml MACS buffer. This solution was
split into 3 tubes and 11JI of 1/10 diluted beads was added, a different bead type
for each tube. The tubes were incubated on a roller for 30 minutes at 4°C to allow
binding and subsequently placed on a magnet to collect the beads. The beads
were washed 5 times with MACS buffer, resuspended in 1001JI of MACS buffer
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and mounted onto microscope slides with a drop of Prolong Gold anti-fade
reagent containing DAPI (Invitrogen) as described in 5.8.

5.11. Control Blood- 30 Minute versus Overnight Incubation

A control blood sample was incubated at 37°C with RBC lysis buffer until lysis
was complete. The solution was centrifuged at 300g for 5 minutes at 4°C to pellet
the remaining cells and the supernatant was discarded. The pellet was washed in
RBC lysis buffer, re-pelleted and the supernatant was discarded. The pellet was
resuspended in 6 ml MAGS buffer and split into 6 eppendorf tubes. 11JI of 1/10
diluted beads was added to each tube, with each bead type being added to two
tubes. One set of tubes was incubated on a roller for 30 minutes at 4°C, while the
second set of tubes was incubated on a roller at 4°C overnight.

Tubes were subsequently placed on a magnet to collect the beads and washed
five times with MAGS buffer. The beads were resuspended in 1001JI MAGS
buffer, pipetted onto coverslips on a magnet, the wash buffer was aspirated and
the beads were mounted onto microscope slides.

5.12. Trypan Blue Staining of Captured Cells

RBC lysis of a patient blood sample was performed as described in 5.1 0. The
solution was centrifuged at 300g for 5 minutes at 4°C and the supernatant was
removed. The pellet was washed in RBC lysis buffer, centrifuged again and the
supernatant was discarded once more. The pellet was resuspended in 1ml
MAGS buffer and 11-11 of 1/10 diluted MCAM beads was added. The sample was
incubated on a roller at 4°C overnight to allow binding. The tube was placed on a
magnet and the beads were washed 5 times with MAGS buffer. The beads were
resuspended in 1OOIJI of MAGS buffer, mixed with 0.1% trypan blue and mounted
on a microscope slide with a drop of Prolong Gold anti-fade reagent containing
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DAPI (Invitrogen), as described in 5.8.

5.13. MACS versus Triton X-1 00 Wash

A2058 and HEK293 cells were harvested with accutase and counted on the ViCeii-XR Cell Viability Analyser (Beckman Coulter). The volume of approximately
106 cells was calculated for each cell type and added to an eppendorf tube. 11-11 of
MCAM beads was added to each tube and the tubes were incubated on a roller
for 30 minutes at 4°C to allow binding. Each tube was then split into two and
placed on a magnet. One set of tubes containing A2058 and HEK293 cells were
washed 5 times with MAGS buffer (2mM EDTA, 0.5% BSA in PBS, pH 7.2), while
the other set of tubes were washed 5 times with 0.2% Triton X-100 in PBS.
Samples were then mounted onto microscope slides with a drop of Prolong Gold
anti-fade reagent containing DAPI (Invitrogen), as described in 5.8.

5.14. Blood Spiking

A2058 cells were harvested with EDTA media (2mM EDTA in DMEM media) and
resuspended in 1Om I of DMEM media containing 10% FBS. 1ml of cells was
diluted 1/10 in a petri dish for spiking into blood. RBC lysis of control blood
performed as described in 5.1 0. The cells were pelleted at 300g for 5 minutes at
4°C and the supernatant was discarded. The pellet was resuspended in MAGS
buffer and 0.5ml was analysed on the Vi-Ceii-XR Cell Viability Analyser
(Beckman Coulter) to determine cell count and viability. The remainder of the
resuspended blood cells were split equally into eppendorf tubes. The desired
number of A2058 cells were pipetted up from the petri dish under a microscope
using a micropipette and spiked into the eppendorf tubes containing control blood
cells. 1, 10, 30, 50 and 100 cell spikes were performed and repeated four times.
Once A2058 cells had been spiked into blood cells, 11JI of 1/10 diluted MCSP
beads was added and tubes were incubated on a roller at 4°C overnight.
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The tubes were placed on a magnet to collect the beads, the supernatant was
removed and the beads were washed 5 times in MAGS buffer containing 0.2%
Triton-X 100. The beads were resuspended in 1001-JI MAGS buffer with 0.2%
Triton-X 100 and mounted on microscope slides with a drop of Prolong Gold
anti-fade reagent containing DAPI (Invitrogen), as described in 5.8. Cells were
then counted by fluorescence microscopy with an epifluorescent Olympus BX51
microscope equipped with an Olympus DP71 camera to determine the number of
spiked cells retrieved following incubation with the beads.

5.15. Non-Specific Binding in Fresh versus 4 Day Old Blood

Two control blood samples were taken from a healthy volunteer and one was
processed immediately while the other was refrigerated and processed after 4
days. RBC lysis of samples was performed as described in 5.1 0. The remaining
' cells were pelleted at 300g for 5 minutes at 4°C and the supernatant was
discarded. The pellet was washed in RBC lysis buffer, re-centrifuged and the
supernatant was again removed. The pellets were resuspended in 3.5ml MAGS
buffer, 0.5ml was analysed on the Vi-Ceii-XR Cell Viability Analyser (Beckman
Coulter) to determine cell count and viability and the remaining 3ml was split into
3 tubes. 11-JI of 1/10 diluted beads was added to each tube, one bead type per
tube, and the tubes were incubated on a roller at 4°C overnight. Tubes were
placed on a magnet and washed 5 times with 0.2% Triton X-100 in MAGS buffer.
The beads were resuspended in 1001-JI of the wash buffer, mounted onto
microscope slides with a drop of Prolong Gold anti-fade reagent containing DAPI
(Invitrogen), as described in 5.8., and viewed by fluorescence microscopy with an
Olympus BX51 microscope equipped with an Olympus DP71 camera.

5.16. Isolation of Circulating Melanoma Cells from Patient Blood

To isolate melanoma cells from patient blood samples, firstly RBC lysis was
performed as described in 5.1 0. The solution was pelleted at 300g for 5 minutes
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at 4°C and the supernatant was discarded. The pellet was washed in RBC lysis
buffer and re-pelleted to remove any remaining unlysed red blood cells. The
pellet was resuspended in 3.5ml of MACS buffer (2mM EDTA, 0.5% BSA in PBS,
pH 7.2) and mixed thoroughly to remove any cell clumps and homogenise the
solution. 0.5ml of this sample was analysed on the Vi-Ceii-XR Cell Viability
Analyser (Beckman Coulter) to determine cell count and viability. The remaining
3m I was split into 3 eppendorf tubes and 11-11 of 1/10 diluted beads were added,
one bead type per tube. The blood cells and beads, suspended in 1ml MACS
buffer, were incubated overnight on a roller at 4 °C.
Tubes were then placed on a magnet to collect the beads and any bead-bound
cells and the supernatant, containing unbound cells, was removed. The beads
were then washed five times with 5001JI of MACS buffer containing 0.2% Triton
X-1 00 to remove any non-specifically bound cells. The beads were resuspended
in 1OO!JI MACS buffer containing 0.2% Triton-X 100 and were pi petted onto
cbverslips on a magnet before being mounted onto microscope slides with a drop
of Prolong Gold anti-fade reagent containing DAPI (Invitrogen), as described in
5.8. Slides were left overnight to allow for full penetration of DAPI for optimal
nuclear staining before being scanned by fluorescence microscopy using an
Olympus BX51 microscope equipped with an Olympus DP71 camera in order to
count the number of cells bound to each bead type. This protocol was performed:
for 21 control blood samples and 33 patient blood samples.

5.17. Statistical Analysis

Results obtained after performing immunomagnetic bead capture on patient and
control samples were analysed using Predictive Analytics Software (PASW)
(IBM, Somers, New York, USA), in order to demonstrate any relationships
between CTC numbers and disease stage.

Firstly, the total numbers of captured cells in patient and control groups were
compared using an independent samples t-test in order to illustrate the difference
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between the mean numbers of captured cells in these two groups. A boxplot was
generated in order to show the difference in the distribution of total captured cells
between patient and control groups.

The relationship between the total cell count and the total captured cells of
patient samples was analysed using the Pearson product-moment correlation
coefficient. This analysis was performed in order to demonstrate the relationship
between these two continuous variables to show whether total cell count was a
confounding variable and therefore influenced the number of cells captured by
immunomagnetic isolation.

The relationships between total captured cells, MCSP cells, MCAM cells, ABCB5
cells and disease stage were determined using Spearman's rank order
correlation

coefficient for

non-parametric data.

This test is

useful for

demonstrating correlation using ordinal, or ranked, variables, such as disease
stage. These analyses were performed to show any correlations between these
variables in order to demonstrate whether disease stage is a predictor of
circulating cell numbers and thus support or refute the hypothesis that the
number of circulating melanoma cells in patient peripheral blood correlates with
disease stage. Patients were also split into non-metastatic (consisting of stage· 0,
I and II) and metastatic (consisting of stage Ill and IV) groups, in order to
demonstrate the difference between the mean number of total captured cells in
metastatic and non-metastatic patients using an independent samples t-test.

Patient 29, who had a total of 232 captured cells, was an extreme outlier and for
this reason, statistical -analyses were performed including and excluding this
patient. It was found that the inclusion of this patient did not have a significant
effect on the outcome and thus, all results are shown with this patient included.
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6. Results

In this study, an assay for the isolation of circulating melanoma cells from patient
peripheral blood samples by immunomagnetic bead capture was developed.
First, target markers were chosen based on current literature and demonstration
of their expression in melanoma cells and tissue by immunofluorescence.
Antibody-coupled immunomagnetic beads were then manufactured and tested
on control and melanoma cell lines in order to optimise the bead capture
protocol. Finally, this protocol was performed for 21 control and 33 patient blood
samples and the results were analysed to determine any relationships between
the number of captured cells and disease stage.

6.1. Demonstration of Chosen Antigen Expression in Melanoma Cell Line
by Immunofluorescence

Immunohistochemistry was performed to demonstrate MCSP, MCAM and
ABCBS expression in A2058 melanoma cells. Demonstration of expression of
these markers in a metastatic melanoma cell line will provide evidence
suggesting these markers will also be expressed in melanoma CTCs and will
therefore be useful target markers for capturing CTCs from patient blood. Alexa
Fluor 488 (A488), conjugated to anti-mouse lgG (for MCSP and MCAM
antibodies) and anti-rabbit lgG (for ABCB5 antibody) were used as secondary
antibodies to detect positive staining in the cells by fluorescence microscopy.
HEK293 cells, as well as A2058 cells with secondary antibody only, were used
as negative controls and therefore should be unstained in order to demonstrate
that melanoma cells were stained specifically as a result of antibodies binding to
target markers on their cell surface.

Fig.6.1.A shows A2058 cells stained with MCSP antibody and anti-mouse lgG
conjugated to A488. All cells were positively stained as a result of lgG-A488
binding to the cell surface via anti-MCSP, confirming MCSP expression in all
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A2058 melanoma cells. In contrast, no staining was observed in HEK293 cells
(Fig.6.1.B) indicating MCSP is not expressed in these cells and further confirming
the specificity of MCSP for A2058 melanoma cells. Therefore, MCSP is a useful
antigen to target for immunomagnetic isolation of circulating melanoma cells.

Fig.6.1.C shows A2058 cells stained with MCAM antibody and anti-mouse lgG
conjugated to A488. Again all cells were strongly positively stained whereas
HEK293 cells were MCAM negative (Fig.6.1.D). This indicates that the MCAM
antibody also binds specifically to A2058 melanoma cells and suggests MCAM is
also a useful antigen to target for capturing circulating melanoma cells from
patient blood. These results show that all A2058 melanoma cells are MCSP and
MCAM positive, however this is not the case in all melanoma cells. MCSP is
constitutively expressed in the majority of melanomas across all disease stages
(Yang et al., 2004) whereas MCAM expression is associated with an aggressive,
' invasive phenotype and is linked with later stage disease (Mangahas et al.,
2004 ). For this reason it is not expected that all circulating cells will be both
MCSP and MCAM positive although it should be the case that all MCAM positive
cells are also MSCP positive. Accordingly, a greater number of MCSP positive
circulating cells than MCAM positive circulating cells are expected to be
observed.

No non-specific staining was observed in the negative control where cells were
stained only with A488 conjugated lgG without primary antibody (Fig.6.1.G). This
confirms that the immunofluorescence observed in A2058 cells stained for either
MCSP or MCAM was specific.

Attempts to demonstrate ABCB5 expression in A2058 melanoma cells by
immunofluorescence with ABCB5 antibody was unsuccessful (Fig.6.1.E). This
negative result is presumably due to the lack of suitability of this specific ABCB5
antibody for immunohistochemistry, an application for which it has not been
tested (Rockland lmmunochemicals, 201 0). The alternative method of flow
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cytometry was used to demonstrate ABCB5 expression in A2058 cells as
reported below.

Figure 6.1. Immunofluorescence of A2058 melanoma cell line with MCSP, MCAM and
ABCB5 antibodies. HEK293 cells were used as a negative control for each antibody.
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6.2. Demonstration of ABCB5 Expression in Melanoma Cell Line by Flow
Cytometry

ABCB5 expression in A2058 melanoma cells was unable to be demonstrated by
immunofluorescence, as illustrated in Fig. 6.1.E. For this reason, flow cytometry
was performed with ABCB5 primary antibody and A488 conjugated secondary
antibody to determine the percentage of ABCB5 expressing A2058 cells. Again,
HEK293 cells and A2058 cells with only secondary antibody were used as
negative controls to demonstrate ABCB5 staining was specific due to ABCB5
antibody binding to ABCB5 on the surface of A2058 cells.

Fig.6.2.A shows the peak fluorescence emission of A2058 cells without antibody,
which has been adjusted to sit entirely within the first decade of the graph in
order to observe any increased fluorescence in samples containing A2058 cells
bound to antibody. All graphs were gated by placing a boundary at the first
decade to separate cells within the first decade (unstained cells) from those with
increased fluorescence. This was performed to demonstrate the percentage of
cells which had increased fluorescence, and were therefore considered positive,
compared with those contained in the first decade of the graph. Analysis of
results following gating of the graphs revealed that 0.44% of unstained A2058
cells had increased fluorescence in Fluorescence Channel 1 (FL 1) and 0.35% of
cells had increased fluorescence in Fluorescence Channel 2 (FL2) (Fig.6.2.A).

Fig.6.2.B shows the fluorescence emission of A2058 cells bound to MCSP
antibody, which was used as a positive control in this experiment. The MCSP
antibody was conjugated to the fluorochrome PE which produces a peak
emission at 575nm and should be seen in FL2. When A2058 cells were stained
with MCSP antibody and analysed by flow cytometry, an increased fluorescence
was observed in FL2 as the bulk of the cell population was visible outside of the
first decade of the graph, demonstrating that the cells were bound to the MCSP
antibody. Gating the graph to determine the proportion of cells outside the first
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decade revealed that 99.56% of cells were MCSP positive shown by an increase
in relative fluorescence.

To identify the number of A2058 cells positive for ABCB5, cells were incubated
with ABCB5 antibody and secondary antibody, conjugated to Alexa Fluor 488
(A488) before being analysed by flow cytometry. A488 produces a peak emission
at 519nm which should be observed in FL 1. As shown in Fig.6.2.C, there is a
slight shift of the cell population in FL 1 which suggests a small number of A2058
cells have increased fluorescence at 519nm and are therefore positive for
ABCB5. Gating of this graph to demonstrate the proportion of cells with
increased fluorescence revealed that 5.05% of these cells appeared outside of
the first decade of the graph in FL 1, which shows that a small population of
A2058 cells are ABCB5 positive. It was expected that only a small percentage of
A2058 cells would be ABCB5 positive as this marker is only expressed on a
subset of melanoma stem cells (Chen et al., 2005).

A2058 cells with secondary anti-mouse lgG, conjugated to A488 alone, without
primary antibody was used as a negative control (Fig.6.2.D.). Gating of FL 1
following analysis by flow cytometry revealed that only 0.52% of cells had
increased fluorescence when no primary antibody was present. This negative
control confirms that ABCB5 is expressed in approximately 5% of A2058 cells
(Fig.6.2.C) and highlights the fact that ABCB5 expression is limited to melanoma
stem cell populations, or at least rare melanoma cells, as opposed to MCSP and
MCAM expression which was observed in all cells of the A2058 melanoma cell
line (Fig.6.1.A and Fig.6.1.C respectively).
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Figure 6.2. Analysis of ABCB5 expression in A2058 melanoma cells by flow cytometry. The
peak emission of A2058 cells alone was adjusted to sit within the first decade of the graph and
graphs were then gated (shown as the horizontal line beginning at 10°) to separate cells with
increased fluorescence from those within the first decade of the graph in order to reveal the
percentage of cells with increased fluorescence in each sample. Cells appearing outside the first
decade of the graph as a result of increased fluorescence were considered positive.
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6.3. Demonstration of MCAM and MCSP Expression in Melanoma Tissue
Sections by Immunofluorescence

Paraffin-embedded melanoma tissue sections were stained with MCAM and
MCSP antibodies to demonstrate expression of these markers in melanoma
tumours by immunofluorescence. ABCB5 staining was not performed due to the
inability

to

stain

A2058

melanoma

cells

with

ABCB5

antibody

by

immunofluorescence. Three sections each of in situ, invasive primary and
metastatic melanoma were stained in order to demonstrate the relative
expression of these markers in melanoma tissue of different disease stages. The
idea of this was to illustrate marker expression relative to disease progression in
order to demonstrate the suitability of MCSP and MCAM as antigens to target in
the isolation of melanoma CTCs and to provide an idea of the number of MCSP
and MCAM positive circulating cells expected relative to disease stage. Specific
staining of tissue sections was confirmed by staining of paraffin-embedded
A2058 cells as a positive control, as A2058 cells were shown to be MCAM and
MCSP positive (Fig.6.1.), and staining of sections with secondary antibody only,
with no primary antibody, as a negative control to observe background
fluorescence and therefore confirm true staining.

Fig.6.3.A and Fig.6.4.A show a section of in-situ melanoma of the superficial
spreading type, which was excised from a patient's left arm. Within the lesion
there were one or two small nests of invasive cells, although invasion was
confined to the superficial epidermis, as described in the patient's histopathology
report. Staining with MCAM antibody and Alexa Fluor 488 (A488), conjugated to
anti-mouse lgG (Fig:6.3.A), revealed small clusters of strongly positive cells
sparsely distributed within the lower epidermis. Staining with MCSP antibody and
A488 (Fig.6.4.A) revealed small clusters of weakly stained cells as well as weakly
stained individual cells scattered throughout the epidermis.
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Fig.6.3.8 and Fig.6.4.8 show a different section of the same superficial spreading
in-situ melanoma seen in Fig.6.3.A and Fig.6.4.A. Staining with MCAM antibody
and A488 (Fig.6.3.8) revealed small clusters of strongly positive cells distributed
throughout the epidermis. Staining with MCSP antibody and A488 (Fig.6.4.8)
also showed small clusters of positively stained cells within the epidermis
although staining was weaker.
Fig.6.3.C and Fig.6.4.C show a section of superficial spreading in-situ melanoma
that has developed within a dysplastic naevus which was excised from the right
shoulder of a patient. Staining with MCAM antibody and A488 (Fig.6.3.C)
revealed a very large area of MCAM expressing cells throughout a large portion
of the epidermis of the section, which may indicate that many cells within this
tumour have an aggressive phenotype although it was excised while in-situ.
Smaller clusters of positive cells, as well as individual positive cells, were also
seen spread throughout the epidermis. Staining with MCSP antibody and A488
(Fig.6.4.C) similarly demonstrated small clusters of MCSP positive cells as well
as positively stained individual cells distributed throughout the epidermis of this
lesion.

Fig.6.3.D and Fig.6.4.D show a section of invasive, ulcerated, nodular,
melanoma excised from the back of a patient. The tumour is 4.77mm in depth
from the stratum granulosum, or granular layer, of the epidermis and the patient
was diagnosed histologically to be at clinical disease stage Ill at the time of
excision of the primary tumour. Staining with MCAM antibody and A488
(Fig.6.3.D) revealed small areas of positively stained cells spread throughout the
epidermis and dermis. Staining with MCSP and A488 antibodies (Fig.6.4.D)
similarly revealed a few individual cells positive for MCSP distributed throughout
the epidermis and dermis.
Fig.6.3.E and Fig.6.4.E show a section of invasive superficial spreading
melanoma excised from a patient's brow. The tumour measures 1.03mm in depth
from the stratum granulosum and the patient was diagnosed as having stage II
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disease at the time of tumour excision. Staining with MCAM and A488 antibodies
(Fig.6.3.E) revealed small clusters of positive cells along with individual positive
cells scattered throughout the epidermis and dermis. Staining with MCSP and
A488 antibodies (Fig.6.4.E) revealed small clusters of weakly stained cells
predominantly within the dermis.

Fig.6.3.F and Fig.6.4.F show a section of invasive superficial spreading
melanoma excised from the left back of a patient. The tumour measured 1.74mm
in depth from the stratum granulosum and the patient was diagnosed as having
stage II disease at the time of primary tumour removal. Staining for MCAM and
A488 (Fig.6.3.F) revealed medium to large areas of positively stained cells, along
with small positive clusters of cells, distributed throughout the epidermis and
dermis. Staining for MCSP and A488 (Fig.6.4.F) revealed small clusters of
positive cells distributed along the lower epidermis. Staining of these cells was
slightly stronger than previous MCSP staining although more patchy.

Fig.6.3.G and Fig.6.4.G show a section of a melanoma metastasis excised from
the skin above the right scapula of a patient. The epidermis in these sections
appeared normal in structure whereas the dermis appeared highly disorganised.
Staining with MCAM and A488 antibodies (Fig.6.3.G) revealed very little MCAM
expression in the epidermis whereas the majority of cells of the dermis were
MCAM positive. Staining for MCSP and A488 (Fig.6.4.G) revealed small clusters
of MCSP positive cells and individual positively stained cells scattered throughout
the dermis.

Fig.6.3.H and Fig.6.4-.H show a section of a melanoma metastasis excised from
the skin of a patient's right arm. Structure of the epidermis in these sections
appeared normal whereas the dermis appeared more disorganised and
unstructured. Staining for MCAM and A488 (Fig.6.3.H) demonstrated that the
majority of cells of the dermis were MCAM positive while the cells of the
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epidermis were negative. Staining for MCSP and A488 (Fig.6.4.H) showed small
to medium areas of positively stained cells throughout the dermis.

Fig.6.3.1 and Fig.6.4.1 show a section of a melanoma metastasis with a lymph
node replaced by malignant melanoma cells. The tissue structure appeared
highly disorganised with densely packed cells of varying morphology. Staining for
MCAM and A488 (Fig.6.3.1) revealed that the entire section was positive for
MCAM. Staining for MCSP and A488 (Fig.6.4.1) revealed medium to large areas
of positive cells distributed throughout the tissue although staining was weak.

Overall, there was an observed increase in the number of positively stained cells
as disease severity increased as the majority of cells in metastatic tissue were
positively stained compared with few positive cells in early stage tissue. This
finding suggests disease progression may be associated with an increase in
melanoma CTCs, especially since the number of MCAM positive cells, which are
associated with aggressive, invasive behaviour, increased with disease severity.
The demonstration of expression of these markers in all tissue sections from in
situ to metastatic disease also supports the proposal that these markers are
useful target antigens for the isolation of melanoma CTCs by immunomagnetic
bead capture.

It is important to note that the MCSP antibody used in this experiment produced
inferior results to the MCAM antibody as there was more MCAM staining
observed than MCSP staining and MCSP staining was significantly weaker.
MCSP is generally noted in the literature to be expressed on the majority of
melanoma cells (Yang et al., 2004); however this was not observed in this
experiment. The less than optimal results obtained for MCSP staining are
thought to be due to difficulties with this particular antibody when used for
immunohistochemistry. Although results were improved by multiple experiments
trialling different antibody concentrations and antigen retrieval methods, results
were not as clear or consistent as those achieved using the MCAM antibody.
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Optimisation of these results would require additional MCSP antibodies to be
trial led.
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Figure 6.3 . Immunohistochemistry of paraffin embedded melanoma tissue sections,
stained with MCAM antibody and secondary anti-mouse lgG conjugated to A488. Red
circles in the 1OOX magnified images illustrate the positively stained area shown at
400X magnification.

49

50

Figure 6.4. Immunohistochemistry of paraffin embedded melanoma tissue sections,
stained with MCSP antibody and secondary anti-mouse lgG conjugated to A488. Red
circles in the 1OOX magnified images illustrate the positively stained area shown at
400X magnification.

51

6.4. Testing the ability of Antibody-Coupled lmmunomagnetic Beads to
Bind Melanoma Cells
A2058 cells were incubated with antiMCSP, anti-MCAM and anti-ABCB5
coupled immunomagnetic beads in
order to test their ability to bind A2058
melanoma

cells,

which

have

previously been shown to express
these markers by immunofluorescence
and

flow

cytometry

(Fig.6.1

and

Fig.6.2. respectively). If the beads bind
these cells successfully then they
should also be able to bind circulating
melanoma

cells

expressing

these

markers. The binding of A2058 cells to
each bead type was observed by
fluorescence microscopy.

Fig.6.5.A shows anti-MCSP coupled
immunomagnetic

beads

bound

to

A2058 cells. This image shows that
anti-MCSP coupled beads (red) are
successful at binding A2058 cells,
which are MCSP positive, as indicated
in Fig. 6.1.A. The ability of anti-MCSP
coupled beads to bind A2058 cells
implies that similar results should also
be obtained when they are used to
bind

MCSP

positive

circulating

melanoma cells from patient blood.

Figure 6.5. Testing anti-MCSP, anti-MCAM and antiABCB5 coupled immunomagnetic beads on A2058
melanoma cells.
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The result of this test also demonstrated that 11JI of anti-MCSP coupled beads
was able to bind many thousand A2058 cells.

Fig.6.5.B shows anti-MCAM coupled immunomagnetic beads bound to A2058
cells. This image shows that anti-MCAM beads also bind A2058 cells
successfully, which are MCAM positive (Fig. 6.1.C .), and should therefore be
able to bind circulating MCAM positive cells from patient blood. The result of this
test demonstrates 11JI of anti-MCAM beads is also capable of binding thousands
of A2058 cells.

Fig.6.5.C shows anti-ABCB5 coupled beads bound to A2058 cells. This result
demonstrates that anti-ABCB5 beads were able to bind only a small percentage
of A2058 cells. Similar results were observed with flow cytometry (Fig.6.2.C.),
suggesting only a small sub-population of A2058 cells are ABCB5 positive which
are likely to be stem or rare melanoma cells. This suggests that the anti-ABCB5
beads bind ABCB5 positive cells specifically and should therefore be successful
at isolating ABCB5 positive circulating melanoma stem ce lls from patient blood .
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6.5. Testing the Binding Capacity of Antibody-Coupled immunomagnetic
Beads by Cell Counting

A2058 melanoma cells were incubated with anti-MCSP, anti-MCAM and antiABCB5 beads and counted on the Vi-Ceii-XR Cell Viability Analyser (Beckman
Coulter) in order to demonstrate the binding capacity of 11JI of each bead type,
i.e. the amount of cells 11-11 of beads is capable of binding. HEK293 cells were
used as a negative control to demonstrate the amount of non-specific binding
resulting from incubation with each bead type.

Table 6.1.demonstrates the binding capacity of 11-11 of anti-MCSP, anti-MCAM
and anti-ABCB5 coupled immunomagnetic beads when incubated with 5x105
A2058 and 5x1 05 HEK293 cells. The cell count was generated using the Vi-CeiiXR Cell Viability Analyser, which counts the number of cells in a representative
portion of the sample to determine the approximate number of cells per ml of
sample.

The results show that 11-11 of each bead type is capable of binding many thousand
A2058 cells, although the number of cells bound to anti-ABCB5 beads seems
high compared to previous results. This test also demonstrated that all th ree
bead types exhibited a high level of non-specific binding as each bead type
bound approximately 50,000 HEK293 cells which are negative for MCSP, MCAM
and ABCB5 (Fig. 6.1.). This high level of non-specific binding of the beads was
possibly due to conjugated antibodies or the beads themselves attaching to the
surface of cells other than through an antibody-antigen bond. This non-specific
binding would need to be overcome before isolating circulating cells from patient
blood to ensure captured cells have been bound specifically based on expression
of a particular marker.
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Table 6.1. The binding capacity of 11-11 anti-MCSP, anti-MCAM and anti-ABCB5
coupled immunomagnetic beads as determined by the Vi-Ceii-XR Cell Viability
Analyser (Beckman Coulter).

Sample

Cells

A2058 + MCSP Beads

0.14x10 6

A2058 + MCAM Beads

0.067 x10 6

A2058 + ABCBS Beads

0.073 x10 6

HEK293 + MCSP Beads

0.046 x10 6

HEK293 + MCAM Beads

0.052 x10 6

HEK293 + ABCBS Beads

0.058 x10 6

6.6. Testing Antibody-Coupled lmmunomagnetic Beads on a Preliminary
Patient Sample
A patient blood sample was tested to assess the number of cells captured by
each bead type . Based on the high binding capacity of 11-11 of beads
demonstrated in Table 6.1., it was decided to use 11-11 of 1/10 diluted beads which
should be sufficient to capture all circulating cells within any patient sample
tested and save on the amount of beads used. Due to the large amount of
unbound cells observed in the patient sample relative to bead-bound cells, and
because the total number of cells (both bound and unbound) was far greater than
expected, it was decided to count only bead-bound cells. Unbound cells were
ignored as it was presumed they were non-specifically bound leukocytes which
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had survived washing. This presumption was supported by the substantial
amount of non-specific binding to HEK293 cells previously observed (Table 6.1.).

The results also show a relatively high number of bead-bound cells captured by
anti-MCAM beads compared to cells captured by anti-MCSP beads (Table 6.2).
This was not expected as MSCP should be expressed in any cells which are
MCAM positive as MCSP is expressed in the vast majority of melanoma cells
(Yang et al., 2004). Due to this result, and given the relatively high number of
anti-ABCB5 bead bound cells, it was thought that many cells had bound nonspecifically to the beads. This was further suggested by the large number of
unbound cells in the sample which were thought to be non-specifically isolated
leukocytes.

Table 6.2. The number of bead-bound cells captured by immunomagnetic
isolation in a preliminary patient blood sample.
Sample

Bead Bound Cells

MCSP Beads

5

MCAM Beads

126

ABCB5 Beads

26

6.7. Comparison of Non-Specific Binding of Beads between 30 Minute and
Overnight Incubation

In order to determine an optimal incubation time that ensures the maximum
isolation of circulating melanoma cells from patient blood without increasing the
amount of non-specific binding, an experiment was conducted using a control
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blood sample to observe the difference in the number of cells bound nonspecifically by each bead type between a 30 minute and overnight incubation.
Therefore, the idea of this experiment was to determine whether an increased
incubation time increases the amount of non-specific binding of the beads. Again,
only bead-bound cells were counted due to the large number of unbound cells
observed in the samples, presumably due to non-specific binding. The resu lts
showed that an overnight incubation did not increase the amount of non-specific
binding (Table 6.3.), suggesting an overnight incubation could be used for patient
samples. The number of bound cells in each sample was however greater than
expected in a control blood sample further suggesting a problem with nonspecific binding of leukocytes to the beads.

Table 6.3. Comparison of the number of bead-bound cells captured from control
blood with immunomagnetic beads for 30 minute and overnight incubation .
Bead Bound Cells
Sample

30mins

Overnight

MCSP Beads

10

2

MCAM Beads

4

8

ABCB5 Beads

5

2

Total Cells

19

12

6.8. Demonstration of Captured Cell Viability by Trypan Blue Staining

In this experiment, a patient blood sample was incubated overnight with antiMCAM coupled immunomagnetic beads, washed with MAGS buffer (2mM EDTA,
0.5% BSA in PBS, pH 7.2) and stained with 0.1% trypan blue solution in order to
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determine whether cells captured by immunomagnetic beads were viable. Trypan
blue does not stain viable cells as it is unable to pass through the intact cell
membrane of a live cell. On the other hand, trypan blue does pass through the
cell membrane of a dead cell and therefore selectively stains dead cells blue.
Following washing of the beads and mixing bead-bound cells with trypan blue
solution, the viability of captured cells was observed by microscopy. Fig.6.6.
shows cells captured by anti-MCAM coupled beads are live as there is an
absence of blue staining within the cells. It was observed that all captured cells
were viable as all were unstained.

Figure 6.6. Trypan blue stain of cells captured by anti-MCAM immunomagnetic beads from
patient blood. The absence of blue cellular staining indicates captured cells are viable.

6.9. Comparison of MACS Buffer and Triton X-1 00 Washing to reduce NonSpecific Binding of Beads
Previous results have demonstrated a relatively high level of non-specific binding
by the immunomagnetic beads when either HEK293 control cells (Table 6.1.) or
control blood samples (Table 6.3.) were utilised. In order to reduce non-specific
binding, a more stringent washing buffer containing 0.2% Triton X-100 was
tested. Previous results had shown that the highest level of non-specific binding
was produced by anti-MCAM coupled beads (Table 6.2., other results not
shown). In this experiment, anti-MCAM beads were incubated with both A2058
and HEK293 cells. Following incubation, both samples were split into two; one
washed with MACS buffer and the other with 0.2% Triton X-100 in PBS in order
to compare the amount of non-specific binding between the samples. Following
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washing, the beads were mounted onto microscope slides and viewed by
microscopy in order to determine whether washing with 0.2% Triton X-100 in
PBS reduced the amount of non-specific binding of anti-MCAM beads to HEK293
cells.

Fig.6.7.A demonstrates the binding of A2058 cells by anti-MCAM coupled beads
following washing with MACS buffer. Fig.6.7.B shows A2058 cells are still bound
to the beads following washing with 0.2% Triton X-100, however the cells have
clumped together making it difficult to distinguish individual cells and therefore
count them. However, based on the number and size of the clumps, as seen in
Fig.6.7.B, it was estimated that the number of cells in the sample was similar to
the number of cells observed following washing with MACS buffer (Fig.6.7.A).
This demonstrated that the Triton X-1 00 has not caused specifically bound
A2058 cells to be removed from the beads during washing. Due to the fact that
5x1 05 cells were used in protocol optimisation experiments, it was thought that
clumping would not be an issue when quantifying cells from patient blood
following Triton X-100 washing, as far lower numbers of captured cells were
expected.

Fig.6.7.C shows a large number of HEK293 cells non-specifically bound to antiMCAM beads which were not removed by washing with MACS buffer. On the
other hand, there were no HEK293 cells observed following washing with 0.2%
Triton X-1 00 in PBS (Fig.6.7.D) demonstrating the effectiveness of Triton X-1 00
at removing non-specifically bound HEK293 cells from anti-MCAM beads. As a
result of this experiment, MACS buffer containing 0.2% Triton X-1 00 was
produced to be used for washing patient and control samples following overnight
incubation with the beads in the final optimised protocol.

Due to the low number of captured cells observed in further testing with 0.2%
Triton X-100 washing, with very few unbound cells seen, it was decided to count
all cells in the sample rather than bead-bound cells only. It was thought that the
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very few unbound cells remaining in the sample would initially have been beadbound in order to be isolated from the sample and survive stringent washing with
0.2% Triton X-100 in MACS buffer. It may have been the case in the few cells
that were not bead-bound during viewing by microscopy that the bead-cell bond
was broken following mounting the cells onto a microscope slide and leaving
overnight for optimal nuclear staining with DAPI. This was suggested as unbound
cells were usually observed extremely closely to at least one bead .
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Figure 6.7. Comparison of non-specific binding of HEK293 cells by anti-MCAM coupled beads between
MACS buffer and 0.2% Triton X-100/PBS washing. 6.6.0 was photographed by light microscopy rather than
fluorescence microscopy for a clearer image of the unbound beads as no cells were present.
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6.1 0. Demonstration of Assay Sensitivity and Specificity by Spiking
Melanoma Cells into Control Blood

In this experiment, increasing numbers of A2058 cells were spiked into control
blood samples and incubated with anti-MCSP coupled beads overnight.
Following washing and mounting the beads onto microscope slides, the number
of cells in each sample was counted by microscopy in order to determine the
sensitivity and specificity of the bead capture assay. The purpose of this was to
determine the proportion of spiked cells that could be captured by the beads
which may be comparable to the percentage of CTCs captured from a patient
blood sample. Due to the variability in the number of cells retrieved with each
spike, the experiment was replicated a number of times in order to determine an
average number of cells retrieved for each number of cells spiked .

Spiking with 0 cells demonstrated that there is a small amount of non-specific
binding in the assay (Table 6.4); although it has been significantly reduced since
Triton X-1 00 washing has been introduced. Due to the presence of some nonspecific background binding it cannot be determined whether a single A2058 cell
was retrieved in the single cell spikes. In actuality, a decrease in the average
number of cells retrieved in a single cell spike compared with a 0 cell spike is
seen, although this is not significant.

The mean values show that as the number of cells spiked increases, so too does
the number of cells retrieved (Table 6.4.). However, it cannot be said from this
experiment exactly how many A2058 cells were retrieved relative to nonspecifically bound cells. Nonetheless, assuming background bind ing rema ins
constant throughout the samples, there is an apparent increase in the number of
A2058 cells retrieved as the number of A2058 cells spiked is augmented.

Although the number of cells retrieved increases with an increase in spiked cells,
it can also be seen that as the number of cells spiked increases, the number of
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cells retrieved becomes more variable. The explanation for this is that an
increase in cell clumping associated with an increased number of spiked cells
was observed. Many of these clumps appeared as a fluorescent blue smear
where individual cells could not be distinguished and therefore could not be
counted. The result of this was that frequently there were more cells retrieved by
the beads than could be recorded as the exact number of cells could not be
determined.

Table 6.4. The number of cells retrieved after spiking control blood with an increasing
number of A2058 cells and incubating with anti-MCSP coupled immunomagnetic beads.

Approximate
Number of
Cells
Spiked

Cells Captured
Spike 1

Spike 2

Spike 3

Spike 4

Mean

0

4

3

5

5

4.25

1

3

4

6

2

3.75

10

9

14

10

6

9.75

30

13

8

21

23

16.25

50

42

31

29

40

35.5

100

11.7

61

19

46

60.75
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Figure 6.8. A graphical representation of the mean number of cells captured after spiking
control blood with an increasing number of A2058 cells and incubating with anti-MCSP
coupled immunomagnetic beads .
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6.11. Comparison of Non-Specific Binding in Fresh and Four-Day-Old
Control Blood

The majority of patient blood samples included in this study were not fresh,
instead averaging 3 days old. For this reason, an experiment was performed with
control blood in order to determine whether increased age of the sample resulted
in increased non-specific binding. In this experiment, two blood samples were
taken from the same volunteer to be processed at different times. The first
sample was processed within hours of it being taken while the second sample
was processed after being refrigerated for 4 days. The results in Table 6.5.
demonstrate that ageing the blood sample did not result in increased non-specific
binding which suggests results obtained from older patient samples are as valid
as those obtained from fresh samples.

Table 6.5. Comparison of the number of non-specifically bound cells in fresh
and 4 day old control blood.
Cells
Sample
Fresh Blood

4 Day Old Blood

MCSP Beads

0

1

MCAM Beads

4

1

ABCB5 Beads

0

0

Total Cells

4

2
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6.12. Results of lmmunomagnetic Bead Capture in Control Samples

Table 6.6. shows the number of cells captured from control blood samples
following immunomagnetic cell sorting with anti-MCSP, anti-MCAM and antiABCB5 coupled beads. All samples were processed within hours of being taken
and analysis with the Vi-Ceii-XR Cell Viability Analyser (Beckman Coulter)
demonstrated that cell counts were relatively high and reasonably consistent.
Furthermore, all samples had a high viability.

Very few cells were captured in most samples demonstrating that the amount of
non-specific binding seen in the assay is low; however some samples produced
a relatively large number of captured cells as a result of cell clumping. Cell
clumping was seen predominantly in samples 2, 13, 14 and 20 and explains the
larger number of cells captured from these samples. This cell clumping did not
appear to be related to total cell count, as demonstrated in Table 6.6. Also, there
did not appear to be an association between clumping and a particular bead
type. The reason for cell clumping in some samples was unclear. It may have
resulted from washing with Triton X-1 00, as this caused A2058 cells to clump
(Fig. 6.7.8.), or it may have been the case that some blood samples had a
tendency to clump more than others as a result of the composition of cells within
the sample which may have been altered, for example in response to injury or
infection. The reason for cell clumps being captured by the magnetic beads was
also unclear. This could have been due to beads becoming lodged in cell clumps
during incubation or a single bead bound cell clumping with other unbound cells.
Overall however, there was a significant difference observed between the
number of cells captured in control samples versus patient samples, as
described in 6.14.1.
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Table 6.6. Results of the immunomagnetic bead capture protocol performed for 21
control blood samples showing the total number of cells captured from each sample as
well as the number of cells captured by each bead type .

Sample

Age of
Sample

1

<1 day

2

<1 day

3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1
<1

day
day
day
day
day
day
day
day
day
day
day
day
day
day
day
day
day
day
day

Total Cell
Count
(x10 6/ml)
4.86
3.83
6.51
2.27
4.71
6.21
3.68
3.27
4.50
4.47
2.27
3.09
4.30
3.11
5.04
2.51
3.92
2.83
2.92
2.26
4.29

Viability
(%)

MCSP
Cells

MCAM
Cells

ABCBS
Cells

Total
Cells

98.9

1

0

1

99.2

0

0
0

8

8

99.0
98.8
99.0
98.9
97.9
98.2
97.8
99.1
99.2
98.7
97 .7
98.7
98.4
99.1
96.4
97.4
98.5
94.7
98.0

0
0
0
0
0
1
0
1
0
3
12
0
0
0
1
1
1
14
3

0
1
1
0
0
0
1
0
2
0
3
0
0
0
2
1
0
3
0

0
1
0
1
0
0
0
0
0
1
1
10
1
1
0
0
1
0
1

0
2
1
1
0
1
1
1
2
4
16
10
1
1
3
2
2
17
4
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6.13. Results of lmmunomagnetic Bead Capture in Patient Samples

Table 6.7. shows the number of cells captured from patient samples following
incubation with anti-MCSP, anti-MCAM and anti-ABCB5 immunomagnetic beads.
Total cell counts in these samples, as determined by the Vi-Ceii-XR Cell Viability
Analyser (Beckman Coulter), were more variable than those of control patients.
This was possibly due to increased age range of the samples, compared with
control samples, which were all processed within hours of collection, or an
increased number of leukocytes in some patient samples as a result of a
heightened immune response to their disease. Although the majority of patient
samples were not fresh, ranging from 0 to 9 days old, all samples had a high
viability, as determined by the Vi-Ceii-XR Cell Viability Analyser, suggesting the
majority, if not all, melanoma CTCs within the sample were viable. Patient
samples included in this study, presented in table 6.7, have been arranged in
order of stage (0-IV) and available clinical information (date of diagnosis of
current primary tumour and information regarding disease recurrence) has been
included in the table for comparison with the number of captured cells.
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Table 6.7. lmmunomagnetic bead capture results for 33 patient blood samples showing the number of cells captured by each
bead type and available clinical data.

Sample

Age of
Sample

Total Cell
Count
(x10"6/ml)

Viability
(%)

MCSP
Cells

MCAM
Cells

ABCB5
Cells

Total
Cells

Disease
Stage

Date of Diagnosis
of Current Primary
Tumour
(month/year)

1

4 days

1.11

97.1

9

2

3

14

0

2

4 days

0.58

95 .8

4

0

3

7

3

3 days

1.24

97.2

7

3

2

4

4 days

0.34

95.7

0

1

5

4 days

0.90

97.7

3

6

4 days

1.49

97.3

7

1 day

1.84

8

1 day

9
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Melanoma Recurrence

Treatment (other
than primary
removal)

01/2009

None

None

0

02/2008

None

None

12

0

10/1999

None

None

0

1

0

05/1996

None

None

2

1

6

0

10/2004

2 primaries diagnosed around
same time

None

55

4

5

64

0

08/2008

2 primaries diagnosed around
same time

None

98.4

13

3

5

21

1

05/2009

First primary removed 09/2008

None

1.12

91.4

21

1

14

36

1

07/2010

Recurre nt disease- first primary
removed 10/1999,2 in-situ
tumours removed 07/2010

None

1 day

1.89

97 .1

15

0

2

17

1

08/2010

Recurrent disease- first primary
removed 10/2006

None

10

4 days

0.85

96.3

35

3

0

38

1

07/2010

None

None

11

3 days

0.83

96 .5

3

0

2

5

1

10/1994

None

None

Sample

Age of
Sample

Total Cell
Count
(x10A6fml)

Viability
(%)

MCSP
Cells

MCAM
Cells

ABCBS
Cells

Total
Cells

Disease
Stage

Date of Diagnosis
of Current Primary
Tumour
(month/year)

Melanoma Recurrence

Treatment (other
than primary
removal)

12

4 days

1.20

97.8

4

0

0

4

1

09/2010

2 primaries diagnosed around
same time

None

13

2 days

2.07

98.3

14

0

1

15

1

07/2010

None

None

14

3 days

1.13

96.1

3

1

1

5

1

12/1997

None

None

15

7 days

1.64

96.1

20

3

7

30

1

05/2009

First primary removed 08/2008

None

16

6 days

0.78

93 .9

0

0

0

0

1

08/2009

None

None

17

<1 day

2.51

98.0

2

1

0

3

2

06/2006

None

None

18

3 days

2.95

70.7

10

1

5

16

2

02/2008

Recurrent primary tumour.
Diagnosed with invasive and insitu tumours at same time.

None

19

4 days

0.73

96.7

8

1

0

9

2

02/2008

None

None

20

3 days

1.39

92.0

3

0

0

3

2

01/2004

Initial invasive primary removed,
second in-situ tumour diagnosed
months later.

None

21

9 days

0.77

94 .0

26

3

9

38

2

02/2005

None

None

22

<1day

5.82

98.1

8

7

1

16

2

03/2010

None

None
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Sample

Age of
Sample

Total Cell
Count
(x10A6fml)

Viability
(%)

MCSP
Cells

MCAM
Cells

ABCB5
Cells

Total
Cells

Disease
Stage

Date of Diagnosis
of Current Primary
Tumour
(month/year)

Melanoma Recurrence

Treatment (other
than primary
removal)

23

1 day

2.28

96.8

1

0

0

1

2

05/2009

Recurre nt primary tumour

None

24

2 days

2.42

95.3

6

3

1

10

2

2005

None

None

25

6 days

2.63

97.3

26

3

6

35

3

07/2007

Nodal metastasis 02/08.
03/2009 new primary

None

26

4 days

1.26

93.2

4

4

2

10

3

04/2005

None

None

27

<1 day

10.44

98.8

43

7

17

67

3

2010

In-situ melanoma removed in
1996. Metastatic melanoma
diagnosed 04/2010

Radiotherapy

28

<1 day

5.36

99.1

2

7

2

11

4

11/2002

9 secondary tumours removed
11/2009

Radiotherapy and
immunotherapy

29

2 days

1.73

95.3

148

12

72

232

4

N/A

Stage IV diagnosis 12/2003. 9
secondary tumours removed
between 12/2003 and 09/2008

Vaccine
(radiotherapy in
2005)

30

4 days

1.54

95.1

4

3

0

7

4

08/2009

Groin metastasis removed
09/2009

None

2 days

0.88

95.3

16

9

9

34

4

08/1996

2010- femoral lymph node and
multiple vertebral metastases
removed
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Figure 6.9. Scatterplot illustrating the tota l number of cells captu red in 21 contro l and 32
patient samples . Patient 29 was not plotted, due to being an extreme outlier, in order to
observe the difference in cell numbers in the remaining samples more clearly.
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Figure 6.10. A graphical representation of the mean number of MCSP, MCAM , ABCBS and
total captured cells for controls and patients relative to disease stage .
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6.14. Statistical Analysis

6.14.1. Total Captured Cells- Controls versus Patients

An independent samples t-test was conducted to compare the total number of
cells captured from patient and control groups. There was a significant difference
in the number of cells captured from patient samples (mean=24.45, standard
deviation=40.92) and control samples (mean=3.71, standard deviation=4.92),
where t(33.44 )=2.88 and p=0.01. Fig. 6.11. shows a boxplot comparison of the
total number of captured cells between patients and controls demonstrating the
significant difference in distribution between the two groups.

Comparison of the Distribution of Total Captured Cells between Control and Patient Samples
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Figure 6.11. Boxplot comparing the distribution of the total number of cells captured in 21 control
and 33 patient blood samples. Outliers are represented by circles and extreme outliers are
represented by stars. Patient 29 was an extreme outlier with 232 cells although their score is not
visible as a result of the limited y-axis scale .
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6.14.2. The Relationship between Total Cell Count and Total Captured Cells

It was thought that the total number of cells in any given patient sample may
have an influence on the total number of cells captured from the sample as there
is a degree of non-specific binding, which may be proportional to the number of
cells in the sample. The relationship between the total cell count of the patient
samples (as determined by analysis with the Vi-Ceii-XR Cell Viability Analyser)
and the total number of captured cells was investigated using Pearson productmoment correlation coefficient. There was an insignificant, extremely weak
positive correlation between these variables (r=0.096, n=33, p=0.59) (Fig . 6.12. ),
demonstrating that there is no relationship between the total number of cells in a
sample and the number of cells captured from the sample by immunomagnetic
isolation. This eliminates total cell count as a confounding factor.
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Figure 6.12. Scatterplot of Total Cell Count vs Total Captured Cells for all 33 patient samples included
in this study. The fit line has been added to the graph to demonstrate the extremely weak positive
relationship between the two variables (r=0.096) which was insignificant (p=0.59).
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6.14.3. Total Captured Cells versus Disease Stage

The relationship between total captured cells and disease stage in patient
samples was investigated using Spearman's rank order correlation coefficient.
There was an insignificant, weak positive correlation between these variables
(r=0.205, n=33, p=0.25) (Fig. 6.13. ), demonstrating that there is no true
relationship between the total number of captured cells and disease stage within
the sample population. A partial correlation between these variables was also
performed controlling for total cell count, which had no effect on the outcome (not
reported). This supports the results illustrated in Fig. 6.12., suggesting total cell
count has no confounding effect on the total number of captured cells.
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Figure 6.13. Scatterplot of total captured cells vs disease stage for all 33 patient
samples included in this study.
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Patient samples were also divided into two groups, metastatic and nonmetastatic, in order to analyse the difference in the mean number of total
captured cells between these two groups by an independent samples t-test.
Group 1 was made up of all non-metastatic patient samples (stages 0, I and II,
n=24) while group 2 was made up of all metastatic patient samples (stages Ill
and IV, n=9). The results showed there was a difference in the number of cells
captured

from

metastatic

patient

samples

(mean=48.44,

standard

deviation=71.45) and non-metastatic patient samples (mean=15.46, standard
deviation=15.61 ),

where

t(8.288)=1.373.

However,

this

difference

was

insignificant (p=0.21) due to the low sample sizes of the groups, especially the
metastatic sample (n=9), and the inclusion of patient 29, an extreme outlier. Fig.
6.14. shows a boxplot comparison of the total number of captured cells between
metastatic

and

non-metastatic

patients

demonstrating

the

difference

in

distribution of total captured cell numbers between the two groups.

Comparison of the Distribution of Total Captured Cells between Metastatic and NonMetastatic Patient Samples

*

2

Non-Metastatic vs Metastatic Disease

Figure 6.14. Boxplot comparing the distribution of the total number of cells captured in non-metastatic
(group 1) and metastatic (group 2) patient samples . Extreme outliers are represented by stars although,
again, patient 29 is not visible on the graph as a result of the limited y-axis scale.
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6.14.4. MCSP Captured Cells versus Disease Stage

The relationship between the number of cells captured with MCSP beads and
disease stage in patient samples was investigated using Spearman's rank order
correlation coefficient. There was an insignificant, weak positive correlation
between these variables (r=0.116, n=33, p=0.521 ), demonstrating that there is no
true relationship between the number of cells captured with MCSP beads and
disease stage within the sample population (Fig.6.15.).
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Figure 6.15. Scatterplot of captured MCSP cells versus disease stage for all 33
patient samples included in this study.
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6.14.5. MCAM Captured Cells versus Disease Stage

The relationship between the number of cells captured with MCAM beads and
disease stage in patient samples was investigated using Spearman's rank order
correlation coefficient. There was a significant, medium positive correlation
between these variables (r=0.486, n=33, p=0.004 ), demonstrating that there is a
significant relationship between the number of cells captured with MCAM beads
and disease stage (Fig. 6.16.).
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Figure 6.16. Scatterplot of captured MCAM cells versus disease stage for all 33
patient samples included in this study.
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6.14.6. ABCB5 Captured Cells versus Disease Stage

The relationship between the number of cells captured with ABCBS beads and
disease stage in patient samples was investigated using Spearman's rank order
correlation coefficient. There was an insignificant, weak positive correlation
between these variables (r=0.190, n=33, p=0.289), demonstrating that there is no
real relationship between the number of cells captured with ABCB5 beads and
disease stage within the sample population (Fig. 6.17.).
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Figure 6.1 7. Scatterplot of captured ABCB5 cells versus disease stage for all 33 patient
samples included in this study.
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7. Discussion

The aim of this study was to quantify CTCs in peripheral blood samples from
Cutaneous

Malignant Melanoma patients

in order to determine the

relationship between the number of CTCs and clinical disease stage.
lmmunomagnetic beads coupled with MCSP, MCAM and ABCBS antibodies
were used to target three different melanoma cell surface antigens for optimal
isolation of melanoma CTCs for subsequent quantification. The use of these
three antibodies also demonstrated differences in circulating cell phenotype
relative to disease stage as a result of expression of different target markers.
Results of this study contribute to the development of a prognostic blood test
that will aid in improving disease management and staging. In addition,
quantification of circulating melanoma cells may prove useful in measuring
treatment efficacy and identifying early stage patients requiring treatment.

7.1. Total Captured Cells

The total number of captured cells for each patient blood sample was defined
as the sum of the number of cells captured with each bead type. This may not
be a true representation of the total number of CTCs within whole blood
samples as antibody-coupled beads would have only captured CTCs
expressing the target antigen and therefore would not have captured other
CTCs negative for that particular marker. It is also the case that cell counts for
each marker may overlap as cells captured with anti-MCAM beads may also
be MCSP positive and vice versa. For these reasons, total captured cell
numbers are approximate values used to give some idea of CTC quantity. In
order to produce a more accurate representation of total CTC numbers in
future experiments, ·all bead types should be added to blood samples in
combination.
7 .2. Controls versus Patients

There was a small amount of non-specific binding observed in control
samples in this study; however, quantification of captured cells demonstrated
that there was a statistically significant difference in the total number of cells
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isolated from control and patient samples. If it is assumed that the amount of
non-specific binding remains relatively constant in all blood samples, this
demonstrates that the cell capture assay employed in this study was
successful at binding circulating melanoma cells. Boxplot analysis of the
distribution of total captured cells between control and patient groups also
illustrated that the number of cells captured in patients was both larger and
more variable than in control samples, which exhibited consistently low levels
of non-specific binding (Fig. 6.11.). Given that the number of cells captured
from patient samples was significantly higher than the number of cells
captured from control samples, it is clear that CTCs were successfully isolated
from patient samples.

Other CTC isolation studies have also demonstrated low level non-specific
background binding. For example, a study by Stott et al. (201 0) isolated CTCs
from metastatic prostate cancer patients and stained captured cells with
Prostate Specific Antigen (PSA), a highly specific prostate cell marker, and
CD45, a leukocyte marker, in order to determine which cells were specifically
bound CTCs versus non-specifically bound leukocytes. It was found that there
was a degree of non-specific background binding to leukocytes in control
samples, ranging from 0 to 8 cells (mean=3) (Stott et al., 2010). This was
similar to the amount of non-specific binding observed in this study, where the
number of cells captured in control samples ranged from 0 to 1T (mean=3. 71 ).

7 .3. Captured Cells versus Disease Stage

Melanoma is an extremely heterogeneous disease and therefore CTCs are
likely to have a variety of different phenotypes. For this reason a number of
antigens were targeted in order to capture as many CTCs as possible from
patient blood samples. Interestingly, there was only a moderate increase in
the total number of captured cells relative to disease stage. Overall, it was
observed that the number of CTCs isolated with anti-MCSP beads was
greater than those isolated with anti-MCAM or anti-ABCBS beads regardless
of disease stage, although similar numbers of MCSP positive cells were
captured across all disease stages. In contrast, although the numbers of
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captured MCAM positive CTCs were small, they significantly correlated with a
more metastatic phenotype and therefore provided insight into the difference
in CTC phenotype relative to disease stage.

7.3.1. MCAM Cells versus Disease Stage

Analysis of the correlation between the number of cells captured with anti'

MCAM coupled beads and disease stage revealed a significant relationship
between these variables (r=0.486, p=0.004) when assessed by Spearman's
rank order correlation coefficient. This result indicates that as disease stage
increases so too does the quantity of MCAM positive cells, although the
amount of MCAM cells in all samples was relatively low compared with the
number of MCSP cells. This is the first study to demonstrate a correlation
between melanoma CTC phenotype and disease stage. This finding is
however supported by current literature which details that MCAM expression
in melanoma primary tumours increases with disease severity and is
associated with aggressive and invasive tumour behavior (Mangahas et al.,
2004; Medic & Ziman, 201 0). Due to the aggressive and invasive phenotype
of MCAM positive cells, it may be the case that these cells have increased
tumour-forming capability. Circulating MCAM positive cells may therefore play
a significant role in the extravasation of CTCs and subsequent invasion· of
tissue sites around the body to form of metastases. The fact that the patients
with the three highest quantities of captured MCAM positive cells (patients 33,
29 and 31) are all stage IV patients and have all had multiple metastases
supports this idea.

7.3.2. MCSP Cells versus Disease Stage

Interestingly, in contrast to results obtained for MCAM positive CTCs, analysis
of the correlation between MCSP positive captured cells and disease stage
demonstrated a weak positive relationship when assessed by Spearman's
rank order correlation coefficient (r=0.116), however this was not statistically
significant (p=0.52). MCSP is constitutively expressed in the majority of
melanomas and is not related to disease progression (Yang et al., 2004);
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however an increase in the number of MCSP positive CTCs was expected in
metastatic patients compared with non-metastatic patients. In previous
studies using anti-MCSP coupled immunomagnetic beads to isolate CTCs
from melanoma patient blood samples, a correlation between CTC positivity,
where a sample was positive if CTCs were isolated, and disease stage has
been shown (Ulmer et al., 2004). Although MCSP positive CTCs were
quantified in this study, the relationship between CTC quantity and disease
stage was not determined as CTCs were only detected in 26% of samples
tested.

Increased numbers of CTCs are expected to be found in later stages of
disease when cells of the primary tumour are more invasive or metastatic and
are therefore able to escape the primary tumour and enter circulation.
However, the results presented here suggest that in fact this may not be the
case. In support of this finding, several reports indicate that a large number of
cells are simply sloughed off the tumour regardless of stage (Bockhorn et al.,
2007). However, a stronger relationship between MCSP positive cells and
disease stage may be shown with an increased sample size.

7.3.3. ABCB5 Cells versus Disease Stage

Similarly, statistical analysis using Spearman's rank order correlation
coefficient showed a weak positive correlation between cells captured with
ABCBS beads and disease stage (r=0.190), however this was not statistically
significant (p=0.29). Like captured MCAM cells, the number of captured
ABCBS cells was low compared with MCSP cells, often comparable to the
amount of background binding observed in control samples. This is the first
study to date detailing numbers of circulating melanoma stem cells in patient
peripheral blood. The number of melanoma stem cells in circulation relative to
non-stem circulating cells appears low although similar to expected values
based on demonstration of ABCBS expression in the A2058 melanoma cell
line, which suggested ABCBS was associated with rare melanoma cells (6.2.).
An interesting point to note is that the patients with the three highest numbers
of ABCBS positive cells (patients 8, 27 and 29), although all of different
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disease stages, have all had the disease for many years; patient 8 was
diagnosed in 1999, patient 27 in 1996 and patient 29 was diagnosed with
stage IV disease in 2003. Furthermore, all three of these patients have
recurrent disease. It may be the case that the large number of captured
ABCBS cells in these patients is related to disease recurrence, as the
proposed role of ABCBS positive melanoma stem cells is in tumour
maintenance and renewal (Boiko et al., 2010; Sekulic et al., 2008).

7.3.4. Total Captured Cells versus Disease Stage

It is interesting to note the number of captured cells in patients with early
stage, non-metastatic disease. This is an important finding demonstrating that
CTCs are indeed present at early stages and may account for the significant
number of patients with early stage disease who suffer recurrence, sometimes
years after removal of the primary tumour (Jacket al., 2006; Koyanagi et al.,
2005a; Weight et al., 2006).

Analysis of the correlation between total captured cells in patient samples and
disease stage showed that there was no significant relationship. There was a
weak positive correlation between these variables (r=0.205) and there was a
differe-nce in the mean number of total captured cells between non-metastatic
(stage 0, I and II) and metastatic (stage Ill and IV) patients (Fig. 6.1 0.).
However, these findings were not statistically significant (p=0.25 and p=0.21
respectively), possibly due to the small sample size. If more patient samples
were included in the study, especially metastatic patient samples, these
relationships may have approached significance as it was expected to see a
significant increase [n the number of CTCs at least between non-metastatic
and metastatic patients, if not across all disease stages. Again, however, it
may be the case that cells are sloughed from the primary tumour and enter
circulation regardless of an invasive phenotype (Bockhorn et al., 2007),
resulting in similar numbers of CTCs across all disease stages. If this is the
case then it may be the phenotype of CTCs that significantly differs relative to
disease stage rather than the number of cells, as suggested by the significant
increase in MCAM positive cells relative to disease stage as reported in 7.2.1.
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7.4. Numbers of Captured Cells

It has been suggested that CTCs circulate in patient blood at an approximate
concentration of 1 in 106 to 107 blood cells (Krivacic et al., 2004). In the
patient samples used in the study, the mean total cell count was 2.21 x1 06/ml
in a 3.5ml sample, which equates to 7.74x10 6 cells, although this was post red
blood cell lysis. The mean number of cells captured from these patient
samples, containing 7. 74x1 06 total cells on average, was 24.45. When taking
into account the presence of non-specific background binding and the fact
that only leukocytes were counted and not erythrocytes, resulting in a far
lower total cell count, the number of captured cells observed is reasonably
close to the number of cells

expected

based on the approximate

concentration of CTCs in the blood of cancer patients.

Later stage metastatic patients may occasionally show far greater numbers of
CTCs, such as the case with patient sample 29, and overall showed a greater
range in the number of total captured cells compared with non-metastatic
patients (Fig.6.14.). This variation in the number of CTCs captured in
metastatic patients has been confirmed in other studies, for example, a study
by Ulmer et al. (2004) captured between 1 and 456 CTCs in stage Ill patients
(median=2) and between 1 and 2410 CTCs in stage IV patients (median=5)'.

This variation in the number of CTCs seen in metastatic patients has also
been observed in other malignancies. For example, Stott et al. (201 0)
quantified CTCs in metastatic prostate cancer patients using an antibody
coated chip which binds CTCs during mixing of patient blood. The results of
this study showed that the number of CTCs in metastatic prostate cancer
patients ranged from 12 to 3167 per ml of blood. The variation in the number
of CTCs demonstrated in this study and by Stott et al. and Ulmer et al. may
reflect variations in patient immune responses, disease history or individual
responses to treatment.
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7.5. The Influence of Patient Melanoma Recurrence on the Number of
Captured Cells

Table 6.7. shows all available information regarding the history of melanoma,
including date of diagnosis of the most recent primary tumour and clinical
history, for all 33 patients included in this study. This information may go
someway to explaining the number of captured cells in some patients,
although trends are difficult to determine as a result of huge variation in time
since diagnosis and disease history within the small sample population.

Despite the absence of trends, there are some interesting results, where the
total number of captured cells seems to be at least somewhat explained by
the patient's history of the disease. Patient 4 was diagnosed with in situ
melanoma in 1996 and since excision of the tumour, there has been no
disease recurrence reported. The total number of cells captured in this patient
was 1, which is less than the mean number of cells captured from control
samples (mean=3.71 ), suggesting that this patient has no CTCs, which is
expected since the patient has been disease free for over 14 years. Patient 29
has stage IV disease and had the largest number of total captured cells of any
patient included in this study (232). This patient has had stage IV disease
since 2003 and had nine separate secondary tumours removed in the five
years following stage IV diagnosis. This large number of metastases along
with the length of time this patient has had late stage disease may explain the
large number of cells captured from this patient.

Although it appears that some extreme high and low numbers of cells can be
explained by clinical. history of the disease in some patients, there are other
radical values which cannot be explained from the available information. For
example, patient 6, a stage 0 patient with no disease recurrence had a large
number of captured cells (64). Instances such as this make it difficult to
determine any apparent relationships between the number of captured cells
and clinical history of the disease. However, the large number of CTCs in this
patient may indicate a risk of disease recurrence since primary tumour
removal occurred in 2008 (Table 6.7.).
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7.6. The Influence of Treatment on the Number of Captured Cells

From the data available for patients included in this study, it is difficult to say
whether treatment type has an influence on the number of circulating cells
since only five patients were undergoing treatment at the time blood samples
were taken (Table 6.7). Because of this and the fact that each of these five
individuals is undergoing a different type, or combination of treatments, it is
impossible to determine any trends in the results. Instead it can only be
speculated as to whether the treatment any of these patients is undergoing
has had an effect on the number of cells captured by immunomagnetic
isolation.

Patient 28, with stage IV disease, is currently undergoing a combination of
radiotherapy and immunotherapy to combat their serious disease which has
resulted in multiple metastases in various locations. The total number of cells
captured from this patient's blood sample was 11, which is relatively low. It is
possible that this combination of treatments is having some effect lessening
the number of CTCs in this patient although due to limited information, this is
difficult to determine. It was also noted that this patient sample had a relatively
large amount of clumping, which resulted in a count lower than the actual
number of cells present, as many cells could not be distinguished within these
clumps.

Patient 29, also with stage IV disease, has received a melanoma vaccine, as
other more standard cancer therapies have been unsuccessful at treating
their serious disease. This patient had by far the highest total number of
captured cells which_may indicate that their treatment is ineffective at reducing
the number of CTCs, and may therefore be ineffective at reducing the risk of
metastasis formation. In contrast, patient 33, who recently had multiple
metastases removed, had a relatively low number of total captured cells
following adjuvant therapy, indicating that their treatment may have been
successful at reducing CTC numbers. These examples suggest that the
number of CTCs captured from patient blood samples may be indicative of
patient treatment success, although it is difficult to determine due to the small
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number of patients who were undergoing treatment, or had recently
undergone treatment other than surgery, at the time of blood collection.

7.7. Limitations of the Study
7. 7. 1. Non-Specific Binding
A few problems arose with the final protocol used for isolating CTCs which
impacted on the results of this study. Firstly there was an issue with nonspecific binding of the beads resulting in cells being isolated from control
blood samples. The initial high level of non-specific binding observed was
reduced with the addition of 0.2% Triton X-1 00 to the washing buffer; however
a low level of background binding remained. It is unclear whether this nonspecific binding was due to the antibody conjugated to the beads binding nonspecifically, control blood cells aberrantly expressing target markers, as a
result of being ex vivo, or Fe receptors on the surface of immune cells binding
antibody. There are a several products available that could be tested in future
experiments in order to ensure these problems are not occurring. Firstly there
are blood collection tubes designed to inhibit abnormal gene expression in
blood cells, thus reducing the chance of them binding to antibody as a result
of atypical marker expression. For example, Cyto-Chex Blood Collection
Tubes (Streck, Omaha, USA) contain a cell preservative which maintains the
integrity of blood cell marker expression for up to 7 days which would inhibit
aberrant expression of melanoma markers in these cells. There are also a
number of Fe receptor blockers available, which inhibit antibodies binding to
Fe receptors on the surface of cells such as B cells, monocytes, and
macrophages in order to reduce non-specific binding of antibodies to these
cells. Melanoma cells, like the majority of tumour cells, are also Fe receptor
expressing

cells

and

therefore

Fe

receptor

blocking

would

ensure

immunomagnetic beads are binding to melanoma cells as a result of the
coupled antibody binding to its target marker rather than to Fe receptors on
the cell surface.
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7. 7.2. Cell Clumping

There was also an issue with clumping in samples, which resulted in clumps
of cells forming during overnight incubation, which were removed by washing
of the beads, or smaller clumps of cells forming, which survived washing and
were seen during microscopy. Formation of cell clumps during incubation may
have resulted in CTCs being lost during washing if they became a part of the
clumps, whereas the presence of smaller clumps were a problem during cell
counting by microscopy. These clumps often appeared as smears in which
very few or no cells could be identified. This often resulted in a cell count less
than the actual number of cells in the sample as only cells identified without
doubt were counted. It is unsure whether these were clumps of melanoma
cells, clumps of blood cells or a mixture of both. They could have been
isolated from the rest of the sample as a result of magnetic beads becoming
entangled in a cell clump or unbound cells clumping with bead bound cells
resulting in clumps becoming bound by magnetic separation. Clumping was
not observed in all blood samples and it did not appear to be related to either
total cell count or the age of the sample. This suggests that some samples
had a tendency to clump more than others possibly due to the cell
composition of the sample.

7. 7.3. Captured Cell Numbers in Early Disease Stages

Results of this study demonstrate that CTCs are indeed present at early
clinical disease stages, which may account for the significant number of
patients with early stage disease who suffer recurrence. In some cases
however, the number of cells captured in early stage, non-metastatic patients
was much larger than expected. This could have been due to increased nonspecific binding in some patient samples, however, if it can be assumed that
the amount of background non-specific binding is reasonably constant, and is
similar to the amount of non-specific binding observed in other studies (Stott
et al., 201 0), there may be another explanation for this. It doesn't appear that
a large number of captured cells in early stage patients, for example patients
6, 8 and 10, was related to the total cell count of the patient sample, which
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suggests it may be the cell composition of the sample that has resulted in an
increased number of bound cells. As discussed, there may be an issue with
bead bound antibodies binding to Fe receptors on the surface of leukocytes. It
could be the case therefore that if a patient has a heightened immune
response to their tumour, which results in an increase in Fe receptor
expressing cells, there may be an increase in non-specific binding. Of course
it would also be case that metastatic patients would have a heightened
immune response to their disease, although a large number of captured cells
observed in early stage patients seems unusual and is less likely to be a large
number of CTCs. Alternately, it may be the case that large numbers of cells
enter circulation even at early disease stages although the immune system
perhaps destroys the majority of these cells. Early stage patients with a large
number of CTCs may therefore have a weakened immune response and large
CTC numbers may indicate the possibility of disease relapse. This idea is
supported by the fact that early stage patients with a relatively high number of
captured cells generally had more primary tumours removed (Table 6.7.),
indicating a large number of cells may correlate with a risk for disease
recurrence. To confirm this, patients would need to be followed for several
years to show an association between CTC numbers and disease recurrence.

7.8. Suggested Future Experiments

7.8.1. Staining Captured Cells

Cells captured

by immunomagnetic isolation should

be stained with

melanoma markers In order to confirm that they are in fact melanoma cells
and not non-specifiqally bound leukocytes. Staining with the same antibodies
used to isolate the cells from patient blood will show whether the cells are
positive for these markers in order to confirm that the beads are binding cells
specifically, via their conjugated antibody. Furthermore, staining these cells
with other melanoma specific markers would demonstrate that they are
melanoma cells rather than other cells that may be aberrantly expressing the
markers that have been targeted in their isolation. Due to the fact that in this
study there was a low level of non-specific binding, which has also been
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observed in other studies (Stott et al., 201 0), staining captured cells is
necessary to reveal the proportion of cells specifically bound verses nonspecifically bound in order to demonstrate the specificity of the assay. Stott et
al. (201 0) in fact used immunostaining to produce a true CTC count in
metastatic prostate cancer patients by staining with PSA (Prostate Specific
Antigen) to confirm CTCs and CD45 (a leukocyte marker) to subtract nonspecifically bound leukocytes from CTC counts.

Here we tested immunohistochemical and immunofluorescence staining using
a number of different protocols and antibodies although results were largely
unsuccessful. A major issue with staining captured cells was that the
magnetic beads themselves strongly fluoresced under all wavelengths of the
fluorescence microscope. This made it difficult for weak staining to be
observed under any wavelength as sufficient exposure resulted in the
fluorescence of the beads overpowering that of the cells. When staining was
weak, this problem was exacerbated by fixing the cells with paraformaldehyde
as it resulted in increased fluorescence of the beads.

Incubating A2058 cells with anti-MCAM beads, fixing them with 2%
paraformaldehyde

and

staining

with

anti-MCSP

and

anti-mouse

lgG

conjugated to Alexa Fluor 546 produced the most successful staining. In this
protocol, cells were washed only after antibody incubation steps. The issue
with fixing the cells before washing was that all non-specifically bound cells
became fixed to the beads and could not be removed by washing. This was
discovered when carrying out this method with HEK293 control cells which
remained bound to the beads following washing, although they were
unstained.

In an attempt to overcome this problem, captured cells were washed 5 times
with 0.2% Triton-X 100 in MAGS buffer, as per usual, before fixing with 2%
paraformaldehyde and subsequently following the staining protocol. When this
method was tested the cells did not stain, possibly because Triton X-100 had
removed the cell surface proteins during washing. This explanation is
supported by the fact that incubating cells with immunomagnetic beads
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overnight in MAGS buffer containing 0.2% Triton X-100, instead of straight
MAGS buffer, resulted in no cells binding to the beads. In order to overcome
this problem, new washing buffers should be tested. It was also found
following this protocol, upon viewing by microscopy, that many cells had
become unbound from the beads and consequently were lost from the
sample. This was possibly due to over-washing the sample, as a result of
performing the standard washing protocol and subsequently washing the cells
following fixing and again after each antibody incubation step. Simply
reducing the total number of wash steps in the protocol may solve this
problem otherwise a different washing buffer may be required.

Due to the fact that strong staining was only seen following fixing the cells,
which also fixed non-specifically bound cells, this method was not suitable for
staining cells isolated from patient samples. This is because a true
representation of the amount of specifically bound cells verses nonspecifically bound cells would not be shown.

Staining the cells within the patient's total blood, following RBG lysis, before
incubation with the beads was also tried. However it was found that washing
and re-pelleting the cells in between antibody incubation steps resulted in loss
of the cell pellet likely due to cell lysis. Problems with these methods need to
be overcome in subsequent experiments in order to develop a sufficient
protocol for staining isolated melanoma cells to sufficiently demonstrate that
the circulating cell isolation protocol is specific and correctly captures
circulating melanoma cells from blood.
7.8.2. RT-PCR of C~ptured Cell RNA

Similarly to staining captured cells, RT-PGR could also be used to detect the
expression of melanoma markers in cells isolated by immunomagnetic beads.
Using primers for the markers used to isolate circulating cells (MGSP, MGAM
and ABGB5) would confirm that captured cells had bound specifically to the
beads as a result of expression of these markers, while amplification of other
melanoma specific markers will confirm that isolated cells are melanoma cells.
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This technique has been performed in other studies which have isolated
melanoma CTCs from patient blood by immunomagnetic beads in order to
confirm that captured cells are in fact melanoma cells and to test for
expression of specific markers in these cells (Kitago et al., 2009).

The Dynabeads mRNA Direct kit (Invitrogen) was used to isolate mRNA from
cells captured by immunomagnetic isolation for use in RT -PCR. This kit allows
mRNA to be isolated from cells and tissue of various types with the use of
magnetic beads covalently coupled to oligo (dT)2s which binds to the polyA tail
of mRNA molecules following cell lysis. This mRNA can subsequently be used
to manufacture eDNA which can be used in a PCR reaction to amplify
melanoma specific markers. Once mRNA had been isolated from captured
cells using the kit and had been converted to eDNA in a reverse transcriptase
reaction, a real-time PCR reaction was performed with primers for GAPDH, a
housekeeping gene constitutively expressed in all cell types. The reason for
this was to show whether enough RNA had been isolated from the cells to
allow PCR to be performed. The result of this real time reaction showed a
small peak on the graph indicating GAPDH was present, although it took more
than 40 cycles to appear which indicated that the amount of RNA isolated
from the cells was extremely low; too low to provide any tangible results. This
result was unsuccessful possibly due to the small amount of RNA contained in
the samples, which consisted of very few cells. However it is feasible that this
method would perform better following protocol optimisation to successfully
isolate RNA from small cell numbers. There are other methods of RNA
isolation suitable for small quantities of RNA that may also be useful for this
application and should therefore be tested, for example RNA isolation with
TRizol reagent (Invitrogen).

7.9. Other Methods of Isolating Circulating Cells

Recent

studies

have

explored

the

use

of

methods

other

than

immunomagnetic bead capture for the isolation of CTCs. Isolating CTCs from
patient blood in order to characterise or quantify them is a relatively new area
of research and as such, there are a number of studies being undertaken to
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develop an optimal method of isolating these cells specifically and efficiently.
As previously discussed, a study by Stott et al. (2010) has implemented an
antibody coated chip that passively mixes patient blood allowing CTCs to
come into contact with antibody bound to the chip which binds these cells and
isolates them from whole blood. This study was able to capture CTCs in 93%
of metastatic prostate cancer patients. Subsequent immunofluorescent
staining confirmed bound cells were CTCs and eliminated false positives by
staining with CD45, a leukocyte marker.

A study by Kojima et al. (2009) used Green Fluorescent Protein (GFP)
expressing attenuated adenovirus specific for telomerase to infect viable
CTCs which could be detected as a result of GFP expression in infected cells
following viral replication. CTCs were detected by automated scanning for
GFP by fluorescence microscopy. Telomerase is expressed in many cancer
cell types and results in maintenance of telomere lengths allowing these cells
to divide without limit rendering them immortal. This study infected blood
samples from patients with a variety of telomerase expressing malignancies
with the GFP expressing virus and it was found that GFP expression could be
detected in all viable CTCs 48 hours after infection.

A study by De Giorgi et al. (2010) isolated CTCs from melanoma patients· by
filtration as melanoma CTCs are larger than other blood cells (>161-Jm).
Captured cells were confirmed as melanoma cells by performing RT-PCR to
detect tyrosinase expression. Results of this study showed that CTCs were
only captured in 62.5% of metastatic melanoma patients suggesting this
technique may be less sensitive than immunomagnetic bead capture and
other methods of <;;apturing CTCs. However, no CTCs were captured in
controls or stage 0 patients suggesting it may be more specific than other
methods of CTC isolation.

Another study employed density gradient centrifugation, a technique used to
separate cell types or cell components based on differences in density, in
order to separate CTCs from whole blood in oesophageal carcinoma patients
(Hoffmann et al., 201 0). RT-PCR was then performed to check captured cells
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for survivin (SW) expression, a marker that varies in expression in response
to treatment in gastrointestinal malignancies, in order to confirm they were
CTCs. SW was detected in 77% of patients showing that this technique was
reasonably successful. These novel techniques, along with immunomagnetic
bead capture, show potential for optimal CTC isolation and therefore need to
be explored further and tested in melanoma patients in order to determine
which method is the most sensitive and specific for isolating circulating
melanoma cells from patient peripheral blood.

7.1 0. Characterising CTCs

As well as allowing CTCs to be quantified, the use of immunomagnetic beads
to isolate CTCs from patient blood would also allow characterisation studies to
be performed in order to analyse the phenotype of these cells. The main idea
of characterising these cells is to demonstrate differences in phenotype
between early stage and late stage cells and to characterise an aggressive
phenotype with high metastatic potential compared with a non-aggressive
phenotype with low metastatic potential. Determining a series of markers
associated with metastasis and aggressive behaviour would allow CTCs
isolated from patient blood to be tested for these markers by RT-PCR in order
to determine the patient's risk of metastasis and disease progression and thus
improve prognosis. Characterising a patient's disease based on CTC marker
expression would also allow specific treatment strategies to be implemented
with the aim of targeting particular cell types in order to more effectively
combat the disease.

7.11. Conclusion

In this study, it has been shown for the first time that the phenotype of
melanoma CTCs can be differentiated since a metastatic circulating cell
phenotype was identified which correlated with disease stage. A statistically
significant relationship was demonstrated between the number of cells
isolated with

anti-MCAM coupled

beads and

disease stage.

MCAM

expression is associated with an aggressive and invasive phenotype with the
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potential for metastasis and therefore quantification of MCAM positive CTCs
may be useful in monitoring disease progression and assessing the
requirement for treatment in early stage patients before the development of
metastatic disease. This would be a significant clinical tool since currently
there is no method of identifying early stage patients requiring treatment
following surgical removal of their primary tumour, as although they are
clinically residual disease free, many of these patients go on to develop
metastatic disease (Jack et al., 2006; Koyanagi et al., 2005a; Weight et al.,
2006).

Results of this study also indicate that there is no significant association
between the total number of captured cells and disease stage. While future
studies with larger patient populations may change this finding, it may indeed
be the case that variation in melanoma CTCs is in the cell phenotype rather
than the number of cells and this too is a significant finding.

There were a number of issues that arose with the development of this cell
capture protocol, such as non-specific binding and cell clumping, which need
to be overcome in future experiments in order to increase the sensitivity and
specificity of the assay. The use of immunofluorescent staining or RT-PCR to
demonstrate marker expression in captured cells also needs to be explored
further to verify that captured cells are in fact melanoma cells. Once these
issues have been addressed and the protocol has been optimised, the
effectiveness of immunomagnetic bead capture to isolate CTCs in melanoma
patients should be compared with other recently developed techniques which
have been utilised for the isolation of CTCs in other malignancies.
Development of an _optimal strategy for the isolation of circulating melanoma
cells will allow the relationship between CTCs and disease outcome to be
further explored

with

the

aim

of improving

prognosis

and

disease

management.
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Development of a Blood Test for Cutaneous Malignant Melanoma

-

Subject Information Sheet -

Purpose
This study will investigate genes, proteins and cells that are abnormally present in the peripheral
blood of patients with Cutaneous Malignant Melanoma or other forms of skin cancer but are not
present in normal healthy individuals. It is anticipated that genes and proteins may be used as
markers to identify cancer cells in the blood of patients as well as provide some indication of
tumour progression.

Background
The genes and proteins that play a role in formation of normal skin cells are for the most part, well
known. A different set of genes and proteins may be switched on or genes and proteins that are
present in normal skin cells may be present in high levels in melanoma tumour cells but not in other
skin cells. The reason for the expression of these genes and proteins in melanoma cells and their
role in tumour development and progression is unknown. In order to provide more accurate
diagnosis and treatments, it is important for medical scientists to understand the signals that lead to
skin cancer formation and progression. Using genetic and protein markers, scientists are developing
a blood test that can detect migrating melanoma cells in peripheral blood. Ultimately the test will be
available for use as in routine diagnostic check ups.
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Procedure
Your participation requires you to donate a small sample of blood. The blood will be taken by a
phlebotomist or your doctor who is working in collaboration with the researchers and may be
providing clinically relevant details relating to the diagnosis of your disease.
As a patient with Cutaneous Malignant Melanoma you will be asked to provide a small quantity
(17 ml) of blood at the time of surgical removal of your tumour, or at routine follow up clinical
visits six months, one year, two years and three years after surgery.
If you are a patient with other forms of skin cancer or a volunteer providing your blood for controls,
then you will only be required to provide your blood on a single occasion.
You may be asked to provide consent for the use of your tissue which has been stored at pathology
laboratories. The tissue required for this study will only be archival tissue no longer required for
diagnostic or treatment purposes. You will not be asked to undergo any further procedures, merely
to provide consent for the use of extraneous tissue.

Risks
In this study, the sample that you provide is a blood sample and there is very little risk to you in this
procedure as only a small volume of blood is required for the test. You may also be asked to
provide access to your archival tissue samples at no risk to yourself

Benefits
Individual:
There are NO individual benefits from this study at this stage. However an examination of your skin
for skin lesions is provided free of charge to you. As the research is at an early stage and no defmite
conclusions can be drawn from the results of the blood test at this stage, results will be provided to
your clinician upon request. However, should an abnormal result be obtained, you or your clinician
will be informed and you will be assisted to make the necessary decisions about any changes to
your treatment in accordance with the NHMRC guidelines for Human Research.
Community:
The results of this study may provide information about the role of genes, proteins and cells in
tumour development and progression. The results may also help identify genes and proteins
involved in tumour metastasis and therefore may at a future date, be used to assist with diagnosis
and treatment of skin cancer, and malignant melanoma in particular.

Confidentiality of Data
Personal details will not be available to all researchers. Only the chief investigator will have your
medical details and your name or patient number. Laboratory researchers will have your medical
details only and your sample will be given a code number to protect your identity. Therefore you
cannot be identified by laboratory researchers but collective results may be published. Your
personal details may be obtained from medical records by your clinician only.
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Subject Rights

Participation in this research is voluntary and you are free to withdraw from the study at any time
and for any reason, without prejudice in any way.
The project has been approved by the Human Research Ethics Committee at Edith Cowan
University (Project No. 2932) and by the Human Research Ethics Committee at Sir Charles
Gairdner Hospital (Project No. 2007-123). These Human Research Ethics Committees are fully
constituted ethics committees and follows guidelines laid down by the National Health and Medical
Research Committee of Australia.
If you have any questions or require any further information about the research project, please
contact:
Mel Ziman on telephone number 6304 5171

If you have any concerns or complaints about the research project and wish to talk to an
independent person, you may contact:
Research Ethics Officer
Edith Cowan University
100 J oondalup Drive
JOONDALUP WA 6027
Phone: (08) 6304 2170
Email: research.ethics@ecu.edu.au
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Appendix 8
PARTICIPANT INFORMATION SHEET

Development of a blood test for Cutaneous Malignant Melanoma
Research on the use of a blood test to monitor Melanoma progression
A/Prof Mel Ziman, Dr Mark Brown, Prof. Michael Millward, Mr. Mark Lee,
A/Prof Robert Pearce, Dr Prasad Kumarasinghe, Dr. Judith Cole,
Mr James Freeman, Ms Tamara Esmaili.

Please take time to read the following information carefully and discuss it with your
friends, family and clinician if you wish. Ask us any question if some part of the
information is not clear to you or if you would like more information. Please do this before
you sign this consent form.
Who is funding this study and where will it be conducted?

I Edith Cowan University
Contact persons:
, Should you have questions about the study you may contact:
A/Prof. Mel Ziman

Phone No.

6304 5171 Mobile: 0419929851(after hours:)

All study participants will be provided with a copy of the Information Sheet and Consent
Form for their personal records.
You may decide to be in the study or not take part at all. If you do decide to take part in
this study, you may stop at any time. However, before you decide, it is important that
you understand why this research is being done and what it will involve.
Whatever your decision, this decision will not lead to any penalty or affect your regular
medical care or any benefit to which you are otherwise entitled.

The following information sheet will explain the study and will include details such
as:
o Why this trial might be suitable for you;
o The possible risks (side-effects) and benefits of the new test;
o The type, frequency and risks of any medical tests or procedures required by the
trial;
o The nature of your participation including how many visits you will make to the
hospital
o Your rights and responsibilities
o Who is funding this study

106

What is the purpose of the study?

This study is a research project in which we are investigating abnormalities in gene and
protein expression in the peripheral blood of patients with Cutaneous Malignant
Melanoma relative to gene expression in patients with other forms of skin cancer and to
normal healthy individuals. It is anticipated that these genes and proteins may be used
as markers to identify melanoma cells in the blood of patients as well as provide some
indication of tumour progression.
Over 900 participants will be involved.

Why is this study suitable to me?

You have been invited to participate in this study because you have been diagnosed with
Cutaneous Malignant Melanoma, or you have been invited to participate because you
have been diagnosed with another form of skin cancer or a mole or you are asked to
participate as a normal healthy volunteer.
How long will I be in this study?

If you agree to participate you will be asked to undergo a skin examination by a
practicing clinician (either a dermatologist or a plastic surgeon). This service will be
provided free of charge if you are a healthy volunteer.
You will then be asked to provide a blood sample.
As a patient the blood sample will be taken before surgical removal of your tumour. If you
are invited to participate as a patient with Cutaneous Malignant Melanoma you will be
asked to provide additional blood samples at the time of routine clinical follow up visits to
your clinician at 6 months, one year, two years and even three years after surgery.
Clinical Visits
Dates
Before Surgical Removal of Tumour
6 Month clinical follow up
1 Year clinical follow up
2 Year clinical follow up
3 Year clinical follow up
What will happen if I decide to be in this study?

-

The study will be conducted over a five year period. If you are a healthy volunteer yol)
will be asked to undergo a free skin examination and provide one blood sample at a
time that is suitable for you.

-

If you are a patient with a skin lesion you will be asked to provide one blood sample
at the time of surgical removal of your lesion.

-

If you are a patient with Cutaneous Malignant Melanoma you will be required to give
a blood sample five times over the course of three years.

-

The amount of blood required for this study is small (only 17 ml per visit). Blood will
be drawn into two different types of blood tubes.
Generally you will not be contacted between visits. If you require general information
about the research at any time then you are able to contact the researchers should
you wish to do so.

-
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-

-

Your blood will be tested relative to blood from other participants and those of healthy
volunteers. Because your sample is only identifiable by a coded number, the
researchers performing the tests will not know which sample is yours.
samples will be stored in the locked freezers during the melanoma research study
conducted at Edith Cowan University and will then be discarded upon completion of
the study or upon your written request.

Are there any reasons I should not be in this study?
The clinical staff collaborating in this study will discuss these with you in detail and will
ensure that this trial is both safe and appropriate for you.

What are the costs to me?
There will be no additional costs over and above your visits to the doctor. Blood will be
taken at the hospital when and where you visit your doctor for treatment and follow up
visits.

What are the possible benefits of taking part?
The results of these studies may be of interest to you and your family and you may
decide whether or not the information may be disclosed to your family.
However, the research will not at this stage provide you with any detailed information
about your health or genetic diseases now or in the future.
Donation of your sample may assist researchers to provide a more detailed and specific
diagnosis of melanoma in the future.

How will my safety be ensured?
In this study, the sample that you provide is a blood sample and there is very little risk to
you in this procedure as only a small volume of blood is required for the test. However
please do not hesitate to contact the study coordinator or your doctor in relation to any
adverse effects you think you are experiencing. If the effects are severe enough, the
doctor may stop your participation in the study. You may also be asked to provide
access to archival tissue samples that are stored in pathology laboratories where they
were used for clinical diagnosis. Should this be the case only archival tissue samples wll
be used and no fresh tissue is required and you will not be required to undergo any
further surgical procedures.
The clinician may find a lesion on your skin or the blood study may produce abnormal
results in which case you and your clinician will be notified and additional clinical tests
will be performed if your doctor feels it is in your best medical interest.

What alternatives do I have to going on this study?
Your participation is voluntary. This study does not affect your treatment or your health.
Your treatment will continue in the same manner whether you decide to participate in the
study or not.
You may wish to discuss with your doctor or the researchers how the test will benefit
patient treatment in the future even though there is no immediate benefit to your own
treatment if you participate in the study.
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What are the possible side effects, risks and discomforts of taking part?

In this study, only a small volume of blood is taken (17 ml) at each scheduled visit so
there is very little risk to you in this procedure. You may suffer a small amount of
discomfort when you donate the blood sample, like the feeling of a pin prick. If archival
tissue samples are used there is no additional risk to you.
The likelihood of side effects from donating blood are small, around 1 in 100.
However should you suffer any side effects please tell your doctor immediately about
any new or unusual symptoms that you get.
What if new information comes along during the study?

Sometimes new information about a blood test becomes available as a study
progresses. You will be told about any information that could be important to you and to
your decision to continue in the study. If you then want to continue in the trial, you may
be asked to sign a revised consent form.
Stopping the study early:

Sometimes a trial needs to be stopped early because of safety concerns, because the
trial is not effective enough, or for other reasons. If this occurs, the reasons will be
explained to you and your treatment will continue as it would have without the test. Your
treatment will not be influenced by the test in any way.
,

What happens at the end of the study?

At the end of the study your visits to your doctor will continue and your treatment will not
be affected by the outcome of the research.
What if something goes wrong?

You will receive the best medical care available during and after the test, but because
these are still relatively new tests, unexpected results may be obtained. In the unlikely
event of risks to your health being identified then you will be provided with the necessary
care.
Medical treatment will be provided at no cost to you for research-related harm. The term
"research-related harm" means both physical and mental injury caused by the product or
procedures required by the trial.
Your participation in this study does not prejudice any right to compensation which you
may have under statute or common law
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Will my taking part in this study be kept confidential?

The researchers will need to collect personal data about you, which may be sensitive,
such as your relevant health information. The researchers may also need to get some of
your health information form other health service providers, eg another hospital,
pathology laboratory, radiographer, GP or other medical specialist.
Any personal or health information will be kept private and confidential. It will be stored
securely and only authorised persons, who understand it must be kept confidential, will
have access to it. Your study details will be given a number so that your identity will not
be apparent. The trial records will be kept at The School of Exercise Biomedical and
Health Science at Edith Cowan University during the study and in a locked archive for at
least 5 years and for a maximum of 15 years from the time the study is closed, and may
be destroyed at any time thereafter.
Authorised representatives of the researchers, the investigating doctors, or University
Human Research Ethics Committees, and other regulatory bodies may require access to
your study records to verify study procedures and/or data. In all cases when dealing with
your information, these people are required to comply with privacy laws that protect you.
The result of the research will be made available to other doctors through medical
journals or meetings, but you will not be identifiable in these communications. By taking
part in this study you agree not to restrict the use of any data even if you withdraw. Your
rights under any applicable data protection laws are not affected.

Will I find out the results of the study?

The value of the research is not known at this time. You will be notified of the results of
the research in general terms at your request and the outcomes of the research as a
whole may be provided to you upon completion of the project.
Who has reviewed the study?

The Edith Cowan University Human Research Ethics Committee and the Sir Charles
Gairdner Hospital Human Research Ethics Committee have reviewed this study and
have given approval for the conduct of this research trial. In doing so this study conforms
to the principles set out by the National Statement on Ethical Conduct in Research
involving Humans and according to the Good Clinical Practice Guidelines.
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The Edith Cowan University and Sir Charles Gairdner Human Research Ethics
Committees have given ethics approval for the conduct of this project.
If you have any questions or require any further information about the research project,
please contact:
Mel Ziman on telephone number 6304 5171

If you have any concerns or complaints about the research project and wish to talk to an
independent person, you may contact:
Research Ethics Officer
Edith Cowan University
100 Joondalup Drive
JOONDALUP WA 6027
Phone: (08) 6304 2170
Email: research.ethics@ecu.edu.au

Or the secretary of the Sir Charles Gairdner Hospital Human Research Ethics Committee
on telephone No. (08) 9346.2999
All study participants will be provided with a copy of the Information Sheet and
Consent Form for their personal records.
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CONSENT FORM

Development of a Blood Test for Cutaneous Malignant Melanoma
Investigators: A/Prof Mel Ziman, Dr Mark Brown, Prof. Michael Millward, , A/Prof. Robert
Pearce, Mr. Mark Lee, Dr Prasad Kumarasinghe, Dr. Peter Heenan, Dr Judy Cole, Mr
James Freeman, Ms Tammy Esmaili
Participant Name:_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
Date of Birth: _ _ _ _ _ __
Address: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __

Phone Number:

---------------------

Email:----------------------Name and address of GP

------------------

, 1. I have been given clear information (verbal and written) about this study and have
been given time to consider whether I want to take part.
2. I have been told about the possible advantages and risks of taking part in the study
and I understand what I am being asked to do.
3. I have been able to have a member of my family or a friend with me while I was told
about the study. I have been able to ask questions and all questions have been
answered satisfactorily.
4. I know that I do not have to take part in the study and that I can withdraw at any time
during the study without affecting my future medical care. My participation in the
study does not affect any right to compensation, which I may have under statute or
common law.
5. I provide consent for my medical history to be made available to the researchers.
6. I agree to take part -in this research study and for the data obtained to be published
provided my name or other identifying information is not used.
If you are unclear about anything you have read in the Participant Information
Sheet or this Consent Form, please speak to your doctor before signing this
Consent Form.

Name of Participant

Signature of Participant

Date

Name of Investigator

Signature of Investigator

Date
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Appendix C

List of Abbreviations

~1-

Microlitre
A488- Alexa-Fiuor 488
ABCB5- ATP-Binding Cassette Subfamily B, Member 5
AJCC- American Joint Committee on Cancer
BSA- Bovine Serum Albumin
CDKN2A- Cyclin-Dependent Kinase Inhibitor 2A
CDK4- Cyclin-Dependent Kinase 4
eDNA- Complementary Deoxyribonucleic Acid
CMM- Cutaneous Malignant Melanoma
CT- Computed Tomography
CTC- Circulating Tumour Cell
DAPI- 4' ,6-diamidino-2-phenylindole
DMEM- Dulbecco's Modified Eagle Medium
DNA- Deoxyribonucleic Acid
EDTA- Ethylenediaminetetraacetic Acid
EpCAM- Epithelial Cell Adhesion Molecule
FBS- Foetal Bovine Serum
Fe- Fragment Crystallizable
FL 1- Fluorescence Channel1
FL2- Fluorescence Channel 2
GAPDH- Glyceraldehyde 3-phosphate dehydrogenase
GFP- Green Fluorescent Protein
HEK 293- Human Embryonic Kidney 293
lgG- Immunoglobulin G
LDH- Lactate Dehydrogenase
MAGE-A3- Melanoma Antigen Gene A3
MAPK- Mitogen-Activated Protein Kinase
MART-1- Melanoma Antigen Recognised by T -Cells-1
MC1 R- Melanocortin-1 Receptor
MCAM- Melanoma Cell Adhesion Molecule
MCSP- Melanoma Associated Chondroitin Sulphate Proteoglycan
MITF- Microphthalmia-Associated Transcription Factor
MRI- Magnetic Resonance Imaging
mRNA- Messenger_ Ribonucleic Acid
NGS- Normal Goat Serum
PBS- Phosphate Buffered Saline
PET- Positron Emission Tomography
PSA- Prostate Specific Antigen
qRT-PCR- Quantitative Reverse-Transcriptase Polymerase Chain
Reaction
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RBC- Red Blood Cell
RGP- Radial Growth Phase
RNA- Ribonucleic Acid
RT -PCR- Reverse-Transcriptase Polymerase Chain Reaction
SW- Survivin
TYRP-1- Tyrosinase-Related Protein-1
TYRP-2- Tyrosinase-Related Protein-2
UV- Ultraviolet
VGP- Vertical Growth Phase
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